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Abstract
Anti-cancer effects by Interleukin 24

By

XUELIN ZHONG

Cancers develop as some cells acquire the ability, either by exogenous stimulation
or by spontaneous mutation, to keep growing despite normal restraints. Up-regulating
translation of oncogenes involved in cell proliferation and tumor development and downregulating translation of tumor-suppressors that normally suppress tumor development
are two most common mechanisms by which cancers develop. Therefore, it is crucial to
study how these proteins get either up-regulated or down-regulated at translational level.
The eukaryotic translation initiation factor, which is composed of subunits such as
eIF4A, eIF4G and eIF4E, is one of the key factors that contribute to efficient translation
initiation. Interleukin 24 (IL-24), otherwise known as melanoma differentiation
associated gene-7 (mda-7), is endogenously expressed by epidermal and immune cells
and involved in wound repairing and fighting inflammation. Overexpression of IL-24 in
cell lines is able to selectively induce apoptosis in various cancer cells while leaving
normal cells intact (Sainz-Perez et al., 2008; Sauane et al., 2003; Persaud et al., 2016;
Lebedeva et al., 2002; Jiang et al., 1996; Gopalan et al., 2007; Chada et al., 2005;
Fonseca-Camarillo et al., 2014). Given this specific killing effect, IL-24 is being studied
extensively and currently in phase II clinical trials as a promising cancer therapeutic.
Sigma 1 receptor and mitochondrial dysfunction have been both found to be involved in
iv

cancer development and treatment as well. The primary focus of this my thesis is that IL24 exerts its anticancer effects by restraining translation initiation of some key mRNAs
for oncogenes by inhibiting subunits of eIF4F complex and inducing mitochondrial
membrane disruption, and Sigma 1 receptor can rescue this killing effect by IL-24.
Inhibition of inhibitory immune checkpoint such as PD-L1 is suggested to be part of the
network by which IL-24 inhibits cancer cells. This work uncovers some new mechanisms
of action that can be exploited to help develop anti-cancer therapeutics mainly composed
of IL-24. Uncovering the details of IL-24-mediated apoptosis in various cancer cell lines
will help develop personalized immune-therapies that can treat tumors in a more efficient
and safer fashion.
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Chapter 1: Background
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1.1 Cancer Development
Cancers are caused by abnormalities that remove normal control on cell growth and
proliferation and allow cells to over-develop despite the physiological signals that
normally would regulate cell growth or induce apoptosis. During the past years, there has
been increasing amount of research that shows interruption with some of the processed in
normal cell functions significantly contributes to the formation and development of some
kinds of cancers. One of these processes is translation initiation, which has a pivotal role
in regulating cell growth, division, differentiation and apoptosis (Buzas et al., 2011; Wahl
et al., 2009; Andoh et al., 2009; Wang et al., 2002; Chen et al., 2020; Tumia et al., 2020).
Proteins are the direct executing molecules for most biological functions in eukaryotic
cells and change of levels of these protein molecules can dramatically alter processes
from cell proliferation, growth, apoptosis to the life course of the entire organism. This is
supported by research results that show unregulated translation initiation has been linked
to genesis and progression of many cancers and inhibition of translation initiation can
restrain cell growth, proliferation and cancer development (Buzas et al., 2011; Wahl et al.,
2009; Andoh et al., 2009; Wang et al., 2002; Chen et al., 2020; Tumia et al., 2020;
Srivastava et al., 2020). Therefore, it is of significant potential for curing diseases like
cancers to study how the process of translation initiation is regulated, specifically in this
work, how Interleukin 24 (IL-24), which is also known as melanoma differentiation
associated gene-7 (mda-7) and a member of the IL-10 cytokine family, can modify
translation initiation step in cancer cells to induce its cancer-only killing effect.
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1.2 IL-24
IL-24 is a secreted cytokine which uses IL-20R1/R2 or IL-22R2/IL-20R2 hetero-dimer
receptors to promote signaling transduction and activator of transcription 1 (STAT1) and
signaling transduction and activator of transcription 3 (STAT3) signaling pathways,
causing expression of genes involved in cell growth and differentiation (Wang et al.,
2002; Sauane et al., 2003; Dumoutier et al., 2001). Hematopoietic cells such as peripheral
blood mononuclear cells (PBMC), T cells, B cells, and monocytes can produce IL-24 in
the presence of many external stimuli and exert various functions including wound repair
and anti-inflammation (Wolk et al., 2002; Poindexter et al., 2005; Maarof et al., 2010; Jen
et al., 2012). Studies have found that IL-24 can be highly induced in Th2 cells along with
IL-10 and expression is dependent on IL-4/STAT6 signaling pathway. At physiological
level, IL-24 has effects in wound healing, development of psoriasis and arthritis, host
defense against organism invasion, and cardiovascular diseases as shown in the figure 1
(Sauane et al, 2003; Dumoutier et al., 2001; Persaud et al., 2016).
In addition to its physiological functions, the anti-cancer effects of IL-24 have been
studied widely in the field. In the past few years, IL-24 has been extendedly studied as a
very promising potential anti-cancer therapeutic due to that this pleiotropic cytokine has a
very potent killing effect on various kinds of cancer cells including colon cancer, breast
cancer, prostate cancer and liver cancer (Mao et al., 2020; Rastegari et al., 2020; Ghavimi
et al., 2020; Deng et al., 2020).
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Figure 1. IL-24 physiological function. In response to certain external stimulation and internal changes, IL24 is at physiological level by monocytes, macrocytes and epithelial cells and binds to IL-20R1/R2 or IL22R2/IL-20R2 receptors to stimulate JAK1/STAT3 signaling pathways and is involved in fighting
inflammation, wound repair and autoimmune diseases including inflammatory bowel disease, ulcerative
colitis and Crohn’s disease.

IL-24’s role in anti-cancer therapeutic was initially discovered by the experiment where
exogenously induced overexpression of IL-24 inhibited tumor growth and only induced
apoptosis in cancer cells and not healthy cells as shown in figure 2 (Lebedeva et al., 2002;
Jiang et al., 1996; Gopalan et al., 2007). And after that experiment, there has been more
and more research showing the same specific and selective anti-tumor effects by IL-24 in
many other different types of cancers including melanoma, glioma and carcinoma of lung,
breast and liver (Chada et al., 2005; Fonseca-Camarillo et al., 2014; Xue et al., 2006;
Bhutia et al., 2011; Xie et al., 2008). Although overexpression of IL-24 has this anticancer effect in so many types of cancers, IL-24 does not have any of this at its
physiological level. And again, there has been no evidence showing that overexpression
of IL-24 has any adverse effects on normal cells such as inhibition of growth or even
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induced apoptosis (Dash et al., 2010; Menezes et al., 2014, 2018).
There are different ways to overexpress IL-24 in cells, such as adenovirus infection,
recombinant protein and cancer-specific oncolytic virus infection. While adenovirus
infection of IL-24 causes cancer-selective killing effect, this method also exerts inhibitory
effects on tumor vascularization, invasion and metastasis (Lin et al., 2014; Zheng et al.,
2007; Li et al., 2013; Li et al., 2011; Yacoub et al., 2008). In addition to working by itself
to kill tumor cells, IL-24 has also been shown to work in orchestration with other antitumor treatments including bevacizumab, which is a monoclonal antibody targeting
vascular endothelial growth factor (VEGF); ZD55-TRAIL, which is an oncolytic virus
that has a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene,
gefitinib, which inhibits epidermal growth factor and other anti-cancer chemotherapeutic
agents such as temozolomide and cisplatin, to which IL-24 can sensitize tumors (Yacoub
et al., 2008; Bhutia et al., 2013; Saeki et al., 2002; Ramesh et al., 2003; Ramesh et al.,
2004; Shi et al., 2007; Sauane et al., 2008; Cai et al., 2012).
Supported by the increasing amount of study, IL-24 is becoming a more and more
favorable potential therapeutic for cancer treatment and management given its tumorselective killing, anti-vascularization and anti-metastatic characteristics that have been
tested in both in vitro and in vivo studies. While we are getting so many positive results in
both basic and clinical research, which has pushed IL-24 as a potential cancer therapeutic
to the phase II clinical trials, the application of IL-24 in cancer treatment and
management is still very much limited to only metastatic melanoma (McKenzie et al.,
2004). In the hope to break this barrier and expand IL-24 application, it is essential to
increase and broaden the efficiency of IL-24 to allow it to benefit more patients with not
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only melanoma but also other types of cancer such as leukemia, lymphoma, colon cancer
and lung cancer and so on. In order to put this idea to test, patients with melanoma,
lymphoma, hepatoma, breast cancer, non-small cell lung cancer, colorectal cancer, head
and neck cancer, and cancers of the parotid gland, lip, kidney, bladder, adrenal gland, and
penis, were enrolled in a clinical trial. The trial applied a non-replicative type 5
adenovirus to induce IL-24 and applied repeated intra-tumoral injections in a doseescalating manner (Eager et al., 2008; Fisher et al., 2003, 2007; Lebedeva et al., 2007;
Sarkar et al., 2007; Cunningham et al., 2005; Tong et al., 2005). In this phase I trial,
researchers wanted to evaluate the safety, pharmacokinetics of vector DNA, and IL-24
protein half-life both at the tumor site and distal from that. Ad.IL-24 was painted with
isosulfan blue dye before being injected to track the distribution over time. Vectorspecific DNA and RNA were detected at the site of injection with highest intensity,
which then faded in peripheral tissues, and minimum expression level was detected up to
3-cm from the injection site. High levels of vector DNA and RNA were detected in
tumors up to 24–48 hours after injection and the levels decreased by 3 logs of magnitude
after 4 days but remained above baseline level after 30 days (Eager et al., 2008;
Cunningham et al., 2005). This trial showed uplifting result that after repeated injections
of Ad.IL-24 directly into the tumor and tissues around the tumor were safe and well
tolerated by the patients. Furthermore, a delightful 44% patient response rate was
prominent in injection sites (Cunningham et al., 2005; Tong et al., 2005). Apparently, in
order to achieve the ultimate goal, which is to expand application of IL-24 to various
types of cancer, we need to first try to unveil the mechanisms behind IL-24’s anti-cancer
effects at different levels, and my research focuses on molecular mechanisms at
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translation level.

Figure 2. IL-24 overexpression kills various types of cancer cells and leaves normal cells intact.
Overexpression of IL-24 by either recombinant protein or adenovirus infection has been tested and shown
killing effects in cancers including prostate cancer, melanoma, lung cancer and colon cancer. Whereas the
same overexpression of IL-24 by either recombinant protein or adenovirus has been shown to have no
effect on normal and healthy cells including prostate epithelial cells, healthy melanocytes, healthy breast
epithelial cells. These tests suggest that IL-24 has a cancer-specific killing effects and not on healthy cell
counterparts. In this work, we tried to define the mechanisms for this cancer-specific killing effect.

1.3 Translation Initiation and eIF4F complex
While cancer cells are heavily dependent on protein synthesis to proliferate, the most
pivotal step during translation process is the initiation step, which involves two major
complexes: ternary complex and eIF4F complex. The eukaryotic Initiation factor 2 (eIF2)
and the initiating methionyl-tRNA (Met-tRNAi) form the ternary complex. The ternary
complex recruits the 40S ribosomal subunit to form the 43S pre-initiation complex. The
43S pre-initiation complex then binds to the mRNA cap with the participation of other
translation initiation factors, such as the eIF4F complex. The pre-initiation complex scans
the 5′ untranslated region (5′ UTR) of the mRNA. While, according to some research
results, these two complexes are coordinated by mTOR complex and casein kinase
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(Kawabe et al, 2002), this work primarily focuses on the eIF4F complex and its
modification by IL-24.
Eukaryotic initiation factors (eIFs), shown in figure 3, are protein subunits that play
important roles in the translation initiation step including stabilizing the mRNA that is
about to be translated as well as recruiting ribosomal subunits to the mRNA followed by
scanning and translation of the mRNA into protein molecules. Several subunits of eIF4
complex will first bind with small 40S subunit of ribosome and the tRNA for consensus
start codon in eukaryotic cells: Met-tRNA, forming a complex called 43S pre-initiation
complex (43S PIC). The 43S PIC is then recruited by eIF4 complex, which is composed
of eIF4A, eIF4E and eIF4G, to the 5’ CAP and scans along the mRNA until it encounters
the start codon AUG on the mRNA, which will attract the large ribosomal subunit 60S to
the translation site to form the entire 80S ribosome and the translation can continue until
the stop codon is reached and translation machinery is released from the mRNA. During
the assembly of eIF4F complex, eIF4E can recognize the target mRNA and binds to its
methyl groups, followed by recruitment of eIF4G subunit to bind to eIF4E, where eIF4G
acts as a scaffold to associate with PABP which in turn attaches to poly-A tail to stabilize
the target mRNA in a loop structure. Then eIF4A will be attracted by eIF4G to form the
final eIF4F complex prior to initiation of translation (Valentina et al., 2016).
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Figure 3. Structure of eIF4F complex. eIF4F complex has 3 subunits: eIF4A, eIF4G and eIF4E. This
complex is assembled at the 5’UTR of the targeted mRNA prior to initiating translation process. eIF4E can
recognize and associate with methyl group at the beginning of the target mRNA, followed by recruiting and
binding eIF4G. eIF4G can associate with poly-A tail binding protein which associates with Poly-A tail of
the target mRNA to stabilize it in a loop structure. Finally, eIF4A is recruited to eIF4G at the frontmost
area of the complex, completing the eIF4F complex. 40 S ribosomal subunit associated with Met-tRNA is
called 43S complex, which is also required for translation initiation to start.

eIF4F could be the key discriminatory factor that is responsible for different translation
rates between different mRNAs. In support to this notion, different mRNAs have shown
varying affinities to eIF4F—a feature that was presented as the levels of mRNA 5’-UTR
secondary structure (Sarkar et al., 1984; Edery et al., 1984; Howard et al., 2020). In
contrast to eIF4F discriminating between different mRNAs based on secondary structures,
translation initiation rates on plain, unstructured mRNAs is not as heavily dependent on
eIF4F, the cap sequences, or ATP (Pestova et al., 2002; Kardos et al., 2020). Also, a
dominant-negative mutation of eIF4A, which is able to inhibit eIF4F activity, shows less
severe inhibition on translation of mRNAs with a less structured 5’-UTR when compared
with transcripts that contain more complex structures (Svitkin et al., 2001; Tupperwar et
al, 2020).
-9-

The eIF4F complex is made of eIF4A1, eIF4A2, eIF4B, eIF4E, eIF4G and eIF4H
subunits. Each of these subunits has their own functions and they work together
cooperatively to make translation happen. For example, eIF4B is essential for ribosomal
subunit 48S initiation complex formation on mRNAs possessing, with even slightest level
of 5’-UTR complexity (Dmitriev et al., 2003) and its depletion results in significantly
decreased cell proliferation, survival and promoted reactivity to camptothecin-induced
cell death (Shahbazian et al., 2010). These results suggest eIF4B’s role in controlling the
translation of mRNAs critical for cell proliferation and survival. Also, there are research
groups that have shown interaction between eIF4E and the mRNA 5’ Cap is crucial for
the translation initiation and this interaction is highly dependent on the binding of RNA
to eIF4GI (Chu et al., 2015; Robert et al., 2020; Diaz et al., 2020). After initial
transformation, growth and proliferation, sometimes tumor cells can acquire the ability to
leave the original site, go through the basement membrane and travel to distant sites in
the organism to form a new colony and new tumor, which is called metastasis. The
complex and specific mechanisms under this phenomenon is still under extensive study,
but one of the subunits of eIF4F--eIF4E stood out as a critical mediator in this process as
initial antisense RNA studies in ras-transformed fibroblast cells showed that mild
decrease of eIF4E can lead up to 90% decrease of metastasis in mice lung cancer.
Following study where these modified cancer cells were injected into mice renal capsule
and failed to observe any infiltration of parenchymal tissue. Moreover, when metastasis
does happen with these cells, they were found to have restored level of eIF4E (Graff et al.,
1995). These early research results suggest a key role of eIF4E for the process of tumor
metastasis, which is considered the ultimate and final irreversible stage for most cancer
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patients. It would be safe to say that it is of huge potential benefit to study more about the
role and contribution of eIF4E in cancer development and metastasis as a future
therapeutic.
In this thesis, the key subunit of eIF4 complex, which needs to be tightly and closely
regulated in cancer cells and influences the expression of mRNAs responsible for
oncogenic signaling, is eukaryotic initiation factor 4A (eIF4A). Mammals possess two
highly related eIF4A paralogs: eIF4A1 (DDX2A) and eIF4A2 (DDX2B), which in
humans are 90% identical at the amino acid level. eIF4A1 is more abundant and better
studied than eIF4A2. In vitro, the two isoforms exhibit similar biochemical activities.
However in vitro, their roles may not be equivalent. Notable differences include the
following, eIF4A1 is predominantly synthesized during active cell growth, whereas
eIF4A2 is produced during growth arrest; Suppression of eIF4A1 leads to increased
eIF4A2 levels, but this change is insufficient to compensate for the ensuing cell death
associated with eIF4A1 loss; eIF4A1 is essential for cell survival, but eIF4A2 is not (Lu
et al., 2014; Raza et al., 2015; Nebigil et al., 2020; Shen et al., 2020).
eIF4A is a helicase that binds to the 7-methylguaniylate cap (m7G) at the 5’ end of the
messenger RNA and unwind mRNAs for translation to occur and continue with the help
from eIF4G and eIF4B (Alexandra et al., 2013; Ali et al., 2011; Alexandra et al., 2014).
Also, there are results that suggest increased activity of the translation initiation factor
eIF4A is linked with more efficient translation of mRNAs encoding for the pro-survival
X-linked inhibitor of the apoptosis (XIAP) and B-cell lymphoma and STAT1 promotes
KRAS colon tumor growth and susceptibility to pharmacological inhibition of translation
initiation factor eIF4A (Wang et al., 2015; Shuo et al., 2016). Furthermore, inhibition of
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eIF4A1 subunit using a small molecule member of the flavegline family is followed by
killing effect of NRAS-mutant cancer cell lines (Bordeleau et al., 2008; Cencic et al.,
2009). There are also many studies showing that targeting eIF4A can significantly impair
the translation initiation step for some crucial proto-oncogenes and appears to be a very
promising therapeutic choice for many kinds of tumors including breast cancer, lung
cancer and melanoma (Gingras et al., 1999; Shen et al., 2019; Webb et al., 2020). In
addition, some groups have shown that Knockdown experiments of eIF4A reduced
proliferation and induced cell death in cancer cell lines (Galicia-Vazquez et al., 2012;
Robert et al., 2014). Furthermore, in murine models, overexpression of eIF4A accelerated
leukemia and sarcoma development as well as drug resistance (Svitkin et al., 2001;
Chang et al., 2020). Several eIF4A inhibitors are currently under investigation and are
thought to exert their effects by translational inhibition of key oncogenes such as c-MYC
(Svitkin et al., 2001; Galicia-Vazquez et al., 2012; Robert et al., 2014).
With so much known about eIF4F complex and its subunits, the idea of fighting cancer
by inhibiting eIF4F complex has been tested widely. For example, depletion of
asparagine has shown inhibition on translation elongation and has been used clinically to
treat acute lymphoblastic leukemia and acute myeloid leukemia in children (Hill et al.,
1967). Moreover, homoharringtonine as an inhibitor of translation elongation has been
approved by FDA to treat chronic myeloid leukemia (O'Brien et al., 1995; Gilles et al.,
2020). There are 3 natural products found to specifically inhibit eIF4A: pateamine A (Pat
A), hippuristanol, and silvestrol (Bordeleau et al., 2005, 2006, 2008). Out of these three
products, silvestrol has been shown to have the most potential to become an anti-cancer
therapeutic given its strongest inhibiting effects on cancer cells and least side effects on
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other normal cells such as liver cells and immune cells in mice studies (Cencic et al.,
2009). Biologic availability of silvestrol after intraperitoneal injection is 100% and it has
a 60% of parental remaining after 6 hours (Saradhi et al., 2011). The inhibition by
silvestrol on cancer cells is most likely due to its inhibition on eIF4A since silvestrolresistant eIF4A mutation can allow cancer cells to survive and proliferate well in
exposure to silvestrol treatment (Sadlish et al, 2013). In accordance with current
speculations, the translation of mRNAs with highly structured 5’-UTR is more liable to
silvestrol treatment compared to those that have simple 5’-UTR (Cencic et al., 2009).
Intriguingly, cancer cells appear to be highly dependent on RNA helicases to keep up not
just general increase in protein production, but also for translation of many oncogenic
mRNAs to promote proliferation and survival (Truitt et al., 2016). The oncogenes that are
more reliant on helicase eIF4A include but not limited to MYC, NOTCH1, MYB, CDK6,
MDM2, CCND3, BCL2, ETS1, ADAM10, LEF1, BCL10, MALT1, ARF6, CCND1,
ROCK1 (Wolfe et al., 2014; Cencic et al., 2009).
As important as eIF4F complex and ternary complex are, they are mostly involved in
mRNA cap-dependent translation where the 5’ cap and 5’UTR sequence play a crucial
role in translation initiation. Whereas in some other mRNAs, 5’ cap and 5’UTR are not as
crucial as they rely more on cap-independent translation where translation of the target
mRNAs does not require the cap sequence and 5’UTR, instead these mRNAs either have
Internal Ribosomal Entry Site (IRES) or TISU sequence that is flanking the start codon in
mRNAs with short 5’UTR for efficient translation to happen. It is the ochestration
between cap-dependent and cap-independent translation that maintains the effactive
translation when cells are under different stress such oxidative stress and heat shock
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stress.

1.4 Sigma 1 Receptor
Historically Sigma1 Receptor (S1R) was considered a traditional receptor. Most
publications regarding S1R describe it in the context of neuropharmacology, in which
S1R modulates ion channels and regulate their respective currents. Also, S1R has long
been known to be involved in addictive effects (Cobos et al., 2008; Maurice et al., 2009).
Over the years, there has been emerging evidence suggesting that S1R is a nontraditional
receptor and instead a trans-membrane protein at ER membrane that can translocate
between cell membranes such as cytoplasmic membrane, ER membrane and
mitochondrial membrane as shown in figure 4 (Yanagiya et al., 2009; Ebru et al., 2002;
Teruo et al., 2003). Scientists have later found that S1R is a protein chaperone, through
whose regulation by specific ligands can have either cytoprotective or cytotoxic effects
(Su et al., 2016) and it functions as a novel and pharmacologically regulated integral
membrane chaperone (Hayashi et al., 2007) and scaffolding protein that regulates ion
channels and relevant ligands biosynthesis in cancers (Crottès et al., 2011).
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Figure 4. Sigma 1 receptor (S1R). Sigma 1 receptor is an integral membrane protein of 26 kDa that is
unrelated to any traditional transmembrane receptor. S1R is predominantly expressed in ER membrane and
functions as a protein chaperone as well as regulating calcium transport between ER and mitochondria.
S1R is over expressed in several pathological conditions, including neurodegenerative diseases such as
Alzheimer disease, Parkinson disease and cancers including esophageal squamous cell carcinoma, prostate
cancer, breast cancer.

S1R is over-expressed in many kinds of cancer cells, including breast and prostate cancer
cell lines (Vilner et al., 1995; Ayadar et al., 2004; Spruce et al., 2004). While in a clinical
study of esophageal squamous cell carcinoma patients, increased S1R expression is
associated with poor prognosis, faster progression, bigger tumor size, higher TMN
staging at the diagnosis and short survival time (Xu et al., 2014). It has also been
observed that this S1R overexpression in the plasma membrane of various human cancer
cell types contributes to the proliferation, invasion and metastasis of these cancers (Van
et al., 2015). Interestingly, S1R antagonists and S1R knockdown via RNAi, have been
shown to decrease cell mass and deactivate key regulators of translation such as
ribosomal protein S6 kinase beta-1 (p70S6K), S6 and 4EBP1 (Kim et al., 2012).
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Moreover, it has been observed that various types of cancer cells that naturally produce
S1R, when treated with S1R putative antagonists become smaller than control cells.
These antagonists of S1R caused cell shrinkage through inhibition of Cap-dependent
translation initiation (Felix et al., 2012). Under certain stressors for a particular period of
time, cells would have increased expression and altered distribution of S1R from MAM
to the periphery of ER system, which then regulates the mobilization of Ca2+ from
mitochondria to ER to fight ER stress and prevent cell death (Teruo et al., 2007). More
recently, Maher and his team discovered that knockdown and inhibition of S1R is
associated with decreased PD-L1 surface expression level, which in turn increases
immune response by T cells on cancer cells in order to suppress tumor development and
progression (Maher et al., 2018). On the other hand, modulation by S1R agonists and
antagonists have also been shown to play a role in cancer. Specifically, branched-chain
ammonium salts, including bis (2-ethylhexyl) ammonium and triisopentylammonium
which act as S1R antagonists, are shown to inhibit tumor growth and development in vivo
(Brimson et al., 2020). In addition to its role in treatment for cancer, S1R has also
displayed some value in cancer diagnosis due to its high expression level across various
types of cancer. For example, Everaert et al. found that a radiolabeled benzamide S1R
ligand 123I-IDAB (123I-N-(2-diethylaminoethyl)-4-iodobenzamide) can be used to detect
melanoma with a high accuracy (Everaert et al., 1997). Following this initial study,
another S1R derivative (123) I - N-(2-diethylaminoethyl)-2-iodobenzamide ((123) IBZA2) was found to be very sensitive for detecting melanoma metastasis (Florent et al.,
2014). In another study in 2017 Haloperidol, a S1R antagonist, was found to effectively
induce cell death in liver cancer (Bai et al., 2017).
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Our group has previously demonstrated that S1R is the common upstream initial signal
transduction molecule involved in IL-24-induced cancer-specific apoptosis (Do et al.,
2013). We have also discovered that IL-24’s action in cancer cells is mediated by an
antagonistic effect of IL-24 on S1R. S1R antagonist-mediated cell death is inhibited by
the prototypic S1R agonist SKF10047 or by overexpression of S1R (Persaud et al., 2016;
Do et al., 2013). Therefore, it is of notable significance, in this work, to elucidate more
about the role of S1R in the effects of IL-24.

1.5 Mitochondria in Cancer
Mitochondria are the most important organelle responsible for cell metabolism and
energy supply and their changes in metabolism in cancer has been studied widely in the
field. Cancer cells have higher metabolic needs and antioxidant defenses compared with
healthy cells. They rely heavily on aerobic glycolysis to meet their energy needs, which is
mainly provided by mitochondria. Furthermore, aerobic glycolysis leads to the
production of large amounts of lactate and pyruvate, causing increased acidity in the
cytoplasm in cancer cells which causes mitochondria to be hyperpolarized compared with
normal cells. This hyperpolarization can also be the result of increased intracellular Ca2+
levels and upregulation of anti-apoptotic Bcl2 protein, leading to increased apoptosis
evasion. So by either inhibiting mitochondrial function or depolarizing mitochondrial
membrane, which can release Cytochrome c to initiate caspase cascade, can largely
induce cancer cell apoptosis. Moreover, the most prominent metabolic modifications in
cancer cells is the upregulated glycolysis even with abundant oxygen available, which is
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named Warburg effect. This aerobic glycolysis process was initially seen as a sign of
impairment of oxidative phosphorylation in cancer cells. Later on with more research
results, increasing amount of evidence suggests that cancer cells are dependent on
mitochondria for the bioenergetic machinery and synthesis of protein, lipid and
carbohydrates (Weinberg et al., 2015), particularly when undergoing external stress, such
as chemotherapy (Vellinga et al., 2015), radiation therapy (Qin et al., 2015) and during
metastasis (Lebleu et al., 2014).
As expected, mitochondrial respiration has been deemed as a promising target for cancer
therapeutics (Weinberg et al., 2015). Considering the importance of mitochondrial
translation products in oxidative phosphorylation, targeting mitochondrial translation
would be a reasonable method to fight cancers and has been proved to be a therapeutic
approach to treat acute myeloid leukemia (Skrtic et al., 2011). While mitochondrial
metabolism and function may change and adapt to cancer cells’ needs, there are some
situations where mitochondria can be damaged and the cells will try to sacrifice them in
order to preserve the entire cell through distinct pathways and mechanisms such as
mitophagy (Ashrafi et al, 2013). These mechanisms can save cells from certain levels of
mitochondrial damage or stress, but when the damage is too severe or lasts for too long
that the cells do not have the chance or capability to handle, or when the salvage
mechanisms are impaired, then those defective and damaged mitochondrial will
accumulate and ultimately lead to cell death and tissue injuries. Besides, IL-24 has
previously been shown to disrupt mitochondrial function and induce ROS production,
shifting cancer cells from pro-survival mode to pro-apoptotic mode contributing to cell
death in prostate cancer cell line as shown in figure 5 (Lebedeva et al., 2003).
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Figure 5. IL-24 overexpression leads to mitochondrial membrane disruption and eventually cancer cell
death. It has been established that inhibition of eIF4A triggers mitochondrial-mediated apoptosis by
inhibiting translation of mRNAs with long 5’UTRs encoding proteins that maintain mitochondrial
structural integrity (e.g., Bcl-2, Mcl1, and BIRC5). Therefore, in this work we investigated the effects of
IL-24 on mitochondrial function and its role in IL-24 killing effects.

1.6 Immune checkpoint blockade in cancer treatment
Using patients’ own immune system to combat cancer has already existed since 1891,
when William B. Coley introduced live streptococcal antigens into a patient with
inoperable tumor to stimulate the patient’s immune system, which then cured the patient.
This invention was the first recorded case of what we now call cancer immunotherapy
(Coley et al., 1893). However, without enough understanding of our immune system and
with fast development of chemotherapies and radiotherapy, immunotherapy has been left
in the shadow in cancer management until a few years ago.
With increased amount of evidence, we found out that immune cells (T cell, B cell and
NK cells) play a crucial part in fighting malignant cells (Chen et al, 2013). Disruption of
the patients’ immune system results in cancer cells escaping from immunosurveillance.
While many mechanisms have been proposed for cancer cell evasion from immune
system, blocking and stimulating some key protein mediators called “immune checkpoint”
by cancer cells has stood out over the past few years, due to the enlightening patients’
responses to therapeutic agents targeting some of these “immune checkpoints” as shown
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in figure 6.
Back in 2013, the “Breakthrough Prize of the Year in Life Sciences” was given to Jim
Allison, who has since led the field in searching for more understanding about the
interaction between human immune system and malignant cells. Specifically, immune
checkpoints are a group of protein molecules that regulate immune system to achieve a
fine balance between eliminating foreign bodies while not harming self and these
checkpoints can be divided into stimulatory and inhibitory checkpoints. Cytotoxic T
lymphocyte-associated molecule-4 (CTLA-4) and programmed cell death receptor-1 (PD1) were the first characterized immune checkpoints, which upon binding to their
respective receptors can inhibit immune system response (Pardoll et al., 2012). These
inhibitory checkpoints have been shown to be used by cancer cells to avoid
immunosurveillance. Hence, blocking CTLA-4 and/or PD-1 signaling pathway with
specific antibodies or drugs could provide patients significant suppression on tumor
growth and long-term survival and this approach is termed immune checkpoint blockade
therapy (ICB). This approach has been tested in multiple types of cancer including lung
cancer, melanoma, liver cancer and sarcoma. In one of the recent studies, Li and
colleagues discovered that inhibition of PD-L1 with MDM2 ligand Nutlin-3 provides
suppression on growth of sarcoma and melanoma (Li et al., 2020).
In 2011 the FDA passed the very first ICB drug ipilimumab, which is an anti-human
CTLA-4 monoclonal antibody, to treat patients bearing advanced melanoma. That move
marked a whole new chapter in cancer treatment. Since then, anti-PD-1 drugs
(pembrolizumab and nivolumab) and anti-PD-L1 drugs (atezolizumab, avelumab, and
durvalumab) have been passed by FDA for treating patients with various types of cancer
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such as non-small cell lung carcinoma, kidney cancer, leading to the awarding of the
2018 Nobel Prize in medicine to Jim Allison and Tasaku Honjo. Given all this promising
initial results and studies, ICBs have been widely tested in patients with various types of
cancer including breast cancer, lung cancer and melanoma with favorable results and
cancer remission (Egen et al., 2019; Melosky et al., 2020).
Despite the impressive clinical response to ICBs, their application has been largely
limited to a small group of cancer patients (Larkin et al., 2015). This limitation is largely
due to primary and acquired resistance that eventually leads to tumor recurrence and
progression. For example, a recent clinical study involving 45 melanoma patients treated
with anti-PD-1 therapy showed only 30% had response to the treatment and tumor
regression while the other patients did not have significant reaction (Hamid et al, 2019).
In order to expand the use and efficacy of ICBs therapies, scientists have dedicated effort
in understanding the mechanism for this resistance. So far, scientists have found that
factors including T cell function, PD-L1 expression and tumor microenvironment can
affect the response rate and efficacy of ICBs. Specifically, when T cell recognition,
activation, differentiation, infiltration, depletion or chemotaxis is disrupted or inhibited, T
cell function in fighting cancer cells will be largely suppressed (Ren et al., 2020).
Furthermore, ICBs can induce life-threatening immune-related adverse events (irAEs) in
certain patients and it is quite expensive to use these drugs for long time. Thus, more
research needs to be done to understand the mechanisms of these drugs as well as
identifying relevant biomarkers for clinical response to ICBs and designing combination
therapies between different ICBs and ICBs with other traditional therapies to achieve
better efficacy, efficiency and cost-effect ratio. In the meantime, other pathways have
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been identified and drugs have been developed in regulating immune system activities,
such as blockage of LAG-3, TIM-3 have been under intensive investigation (He et al.,
2016; Woo et al., 2012; Goldberg et al., 2011). Furthermore, agonists of stimulatory
checkpoints such as ICOS, CD40, as well as molecules that target tumor
microenvironment (TME) components like IDO or TLR have also gained a lot of
attention (Bilir et al., 2017; Siu et al., 2017).
In this thesis, our group has gained some evidence that suggests IL-24 might play a role
in the immune checkpoint regulation as an upstream coordinator to inhibit PD-L1’s
inhibition on T cell activation and function both in vitro and in vivo. With our results, we
have a better understanding about how IL-24 exerts its cancer-selective killing effects as
well as expanding the knowledge about the immune checkpoint blockade application in
more cancer types and hopefully will help clinicians with immunotherapies that last
longer and have milder adverse response from patients.

Figure 6. PD-L1 expression levels and activity are closely related to the immune response to cancer cells
and tumor growth. With high expression levels and increased activity of PD-L1, immune system including
T cells activity and normal response to cancer cells will be inhibited and tumor growth will be uninhibited.
Whereas when PD-L1 expression level and activity are inhibited, T cell and other immune cells can
generate robust response to cancer cells and inhibit cancer cell survival and tumor growth. In this work, we
tried to define if IL-24 can inhibit PD-L1 expression level as a mechanism for its cancer killing effect.

- 22 -

1.7 Research Purpose
One of the goals of this work largely focuses on uncovering how IL-24 treatment in
cancer cell lines can display its cancer-selective killing effects through different signaling
transduction pathways with different intermediators. This goal has been broken down to
specific parts in order to support the phenomenon that IL-24 selectively causes apoptosis
in cancer cells due to it halts the translation initiation step and depletes intracellular
calcium ion store. To further elucidate how IL-24 impairs translation initiation and
calcium mobilization, Si1R, as well as eIF4A1 have been extensively studied in this
project to map their respective roles in IL-24 anti-cancer effects.
Another goal of this work is to expand the application spectrum of IL-24 as an anticancer therapeutic from only melanoma to other types of cancers and also increase the
efficiency of this treatment in melanoma patients. The reason for this goal is due to the
plaguing hurdle amongst cancer treatments that no drug has been developed to work for
many types of cancer, most the treatment can only fight one specific type of cancer and
their efficacy usually drops down significantly after some time into treatment regimen.
Hence, understanding the molecular mechanism by which IL-24 exerts its cancer-killing
effects will potentially help resolve this big hurdle preventing better treatments for cancer
patients.
Also, in this work we try to define the relationship between IL-24 and immune
checkpoints to broaden its usage to more types of cancer with better and longer response
as a thriving immune-therapeutic. To this date, there has been an increasing body of
research showing that by either inhibiting inhibitory checkpoints or simulating
stimulatory checkpoints alone or with other treatment can give a subset of cancer patient
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drastic improvement, but this improvement is either too short or limited to certain
patients (Marin-Acevedo et al., 2018). In order to combat these two major hurdles, we
need more research to uncover the mechanisms behind the response to this kind of
treatment.
The new insights gained in this work will benefit both scientists and physicians in
transiting basic research to clinical studies, which will help develop better treatments for
patients with more specific, more personalized and, most importantly, more widely
applicable methods. This thesis presents some new findings about IL-24’s cancerselective inhibitory effects mechanisms and targets that can help take future cancer
treatments to the next level.
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Chapter 2: Materials and Methods
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2.1 Gene Cloning
E.Coli are transformed with respective gene construct using SIG10 5 alpha Chemically
Competent Cells (Purchased from SIGMA) following the manufacturer’s instructions.
Transformed bacteria are grown in LB liquid media overnight and inoculated on agar
plates, the next day individual colonies were picked and put into LB media to grow
overnight, 24 hours later, bacteria are collected following instruction by Midi-prep kit
(purchased from Qiagen, Cat log #12143).

2.2 Cell culture and Conditions
All human cell lines (cervical cancer: HeLa; breast cancer: MCF-7, MDA-MB-231,
prostate cancer: PC-3, DU-145) were purchased from American Type Culture Collection
(ATCC), maintained per ATCC protocols and utilized within six months of thawing each
vial. Cell lines were grown in a humidified atmosphere at 37°C with 5% CO2 and culture
media was replaced every other day.

2.3 Virus Infection
After attachment within 24 h, cells were infected with the IL-24 expressing replication
defective adenovirus (Ad.IL-24) or the control, a corresponding empty adenovirus vector
lacking exogenous gene (Ad.vector). The adenoviruses were custom made by Vector
Biolabs, Inc. (Philadelphia, PA).

2.4 Transfection of Oligonucleotides
Cells were seeded in 10-cm petri dishes. After reaching 60%-70% confluence, media was
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replaced with Opti-MEM (Thermo Fisher Scientific Inc.; Wilmington, DE, USA) and
cells were transfected with corresponding gene construct, using Lipofectamine 2000
(Thermo Fisher Scientific Inc.; Wilmington, DE, USA) according to the manufacturer’s
instructions. Transfected cells were then incubated at 37°C for a total duration of 24 h
before cells were sub-cultured into 6-well plates and then treated with either empty virus
or Ad. IL-24 virus, followed by dual luciferase assay reading.

2.5 Western Blot Analysis
Cellular protein was extracted using Pierce IP Lysis Buffer (Thermo Scientific, Rockford,
IL) and a mixture of Halt Protease Inhibitor Cocktail 100X (Thermo Scientific, Rockford,
IL) and Phosphatase Inhibitor Cocktail 100X (Cell Signaling Technology, Danvers,
Massachusetts). Fifty-sixty micrograms of protein were applied to a 10% SDS/PAGE and
transferred to nitrocellulose membranes. Membranes were incubated with Odyssey
blocking buffer (LI-COR Biosciences, Lincoln, Nebraska) prior to incubation with
polyclonal or monoclonal antibodies to eIF4A, eIF4E, eIF4G, Cdc25C, XIAP, Mcl1,
BIRCA5, alpha-tubulin, Caspase-3 and β-actin overnight at 4°C. All primary antibodies
were purchased from Cell Signaling Technology (Danvers, Massachusetts). Goat antirabbit IgG (H+L) 800 CW, goat anti-rabbit (680 RD) and/or goat anti-mouse (H+L)
secondary antibodies were applied for 1 h at room temperature (1:25000, LI-COR) prior
to washing with 1X Tris Buffered Saline Tween-20 (TBS-T). Visualization was carried
out with the LI-COR Odyssey CLx imaging system and software.
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2.6 RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRTPCR)
Total RNA was isolated by using the RNAeasy kit (Qiagen). Reverse transcription (RT)
was performed on 5 ng of total RNA with an oligo(dT) primer. cDNA corresponding to 5
ng of total RNA was amplified for 35 cycles by PCR with specific primers as previously
described (Sauane M et al, 2010). Sequence-validated QuantiTec probes for eIF4A,
eIF4B, eIF4G, Cdc25C, c-myc, ornithine decarboxylase, Bcl-2, Mcl1, Birca5, X-linked
inhibitor of apoptosis, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and alphaactin purchased from Qiagen Bio-technology were used for these mRNAs.

2.7 Dual Luciferase Assay
Luciferase reporters (kindly provided by Dr. Ivan Topisirovic) and luciferase assays were
described previously (Gandin V. et al, 2016). HeLa cells were seeded in a 10 cm Petri
dish and next day transfected using 30 uL of Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA), 600 ng of control Renilla (kindly provided by Drs. Yuri Svitkin and Nahum
Sonenberg) and 1.2 ug of the firefly luciferase constructs. The next day, cells were
seeded in triplicate in a 12-well plate and translation of the indicated reporters was
monitored 48 h post-transfection using Dual Luciferase Assay System (Promega,
Madison, WI, USA) according to the manufacturer’s instructions.

2.8 Mitochondrial Membrane Potential Assay
Mitochondrial membrane potential was monitored in intact cells by confocal microscopy
using tetramethylrhodamine ethyl ester (TMRE), which can only accumulate in
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mitochondria when they are active. HeLa cells were seeded on 25 mm cover slips at a
density of 600,000 cells/well, grown for 48 h, and then incubated with JC1 (10 _g/mL)
for 2 h. The cover slip was washed twice and mounted in a cell chamber (ALA Scientific
Instruments, Westbury, NY, USA).

2.9 Annexin V Binding Assay
Cells were trypsinized, washed once with complete medium and PBS, resuspended in 0.5
mL of binding buffer containing 2.5 mmol/L CaCl2, and stained with allophycocyaninlabeled Annexin V (Becton Dickinson Biosciences, Palo Alto, CA, USA) and propidium
iodide (PI) for 15 min at room temperature. Flow cytometry assays were performed as
previously described (Persaud L et al, 2017).

2.10 Mice and mice colon cancer cells
C57BL/6J mice are purchased from The Jackson Laboratory. Colon cancer cells are
purchased from Kerafast. Two 8-week old C57BL/6J female mice were put in one cage
and let accommodate for 2 weeks. On day 0, 1 x1010 MC38 cells were mixed in 100 ul
PBS and injected into each mouse subcutaneously at their right flank. Mice tumors were
observed and measured every day. On day 16, tumors become palpable in each mouse.
185 ul of PBS was injected into tumor 1 and 185 ul of Ad.IL-24 was injected into tumor
2. On day 22, mice were sacrificed and tumors were harvested and measured

2.11 Statistical Analysis
Data was compiled from at least three independent experiments. All results are presented
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as mean ± standard error of the mean (SEM). Unless otherwise indicated, analysis of
statistical significance of differences between groups was determined using two-tailed
Student’s t-test. Only values with P < 0.05 were considered statistically significant.
Statistical differences in the relative mRNA expression profiles were determined with
one-way analysis of variance (ANOVA) using the SPSS Statistics software (http://www01.ibm.com/software/analytics/spss/) on normalized data. Only values with P < 0.05 were
recorded as statistically significant.
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Chapter 3: Eukaryotic translation initiation factor 4A down-regulation mediates
interleukin-24-induced apoptosis through inhibition of translation
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3.1 Introduction
Cancer cells lose the physiologic restraints on the cellular translational machinery,
leading to increase in both global protein synthesis and translation of specific mRNAs
that promote tumor cell survival (Hinnebusch et al., 2016). Translation initiation plays a
critical role in the physiological regulation of cell proliferation, differentiation and
apoptosis. Unrestricted translation initiation not only critically contributes to the
maintenance and progression of cancers but also causes malignant transformation
(Ruggero et al., 2013; Silvera et al., 2010). Two major rate-limiting steps in translation
initiation regulation are the assembly of ternary complex (TC) and eIF4F complexes
(Hinnebusch et al., 2014). Targeting translational control, especially the eIF4F translation
complex is currently at the forefront of the development a promising therapeutic strategy
(Duncan et al., 1983; Galicia-Vazquez et al., 2012).
Dysregulated activity of helicase eIF4A drives transformation to and maintenance of
cancer cell phenotype by reprogramming cellular translation. Interleukin 24 (IL-24) is a
tumor-suppressing protein, which can inhibit angiogenesis, sensitize cancer cells to
chemotherapy, and induce cancer cell-specific apoptosis. As progresses via translation
initiation mechanisms that are dependent either on the 5’cap structure (m7GpppN, where
N can be any nucleotide) or an internal ribosome entry site (IRES) (Lomakin et al., 2000;
Sonenberg et al., 1981). Also, Short 5’ untranslated region (5’UTR) mRNAs are enriched
with TISU (translation initiator of short 5’UTR), a 12-nucleotide element directing
efficient scanning-independent translation. The majority of translation initiation events in
eukaryotes are mediated through cap-dependent translation whereby the 40S ribosomal
subunit is recruited to the vicinity of the mRNA 5’ cap structure by the eukaryotic
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initiation factor 4F (eIF4F) complex (Malka-Mahieu et al., 2017). eIF4F is comprised of
eIF4A (an RNA helicase), eIF4E (the cap-binding subunit), and eIF4G (a large
scaffolding protein for eIF4A, eIF4E, and other initiation factors). Once assembled at the
5’ cap, the 40S ribosomal subunit in association with several initiation factors scans the
5’UTR of the mRNA until it encounters a start codon in a favorable context, followed by
polypeptide synthesis. eIF4A stimulates translation of both capped and uncapped mRNAs
in vitro (Malka-Mahieu et al., 2017).
Our previous studies have shown that a non-replicating adenoviral vector expressing
Interleukin 24 (Ad.IL-24) induces apoptosis selectively in cancer cells, mediated through
phosphorylation of eIF2-alpha (Persaud et al., 2017). The same non-replicating
adenoviral vector expression IL-24 (INGN241) was used in patients with metastatic
melanoma (Ramesh et al., 2010). Indeed, clinical trials in which Ad.IL-24 was
administered by intra-tumoral injection in patients with advanced solid tumors, show
promising results (Cunningham et al., 2005; Tong et al., 2005). We and others have
extensively investigated and reported the underlying apoptotic mechanisms of IL-24
protein treatment and Ad.IL-24 infection in preclinical studies in several cancer cells
including prostate cancer cells (DU-145), melanoma (HO-1), breast cancer cells (MCF-7),
and cervical cancer HeLa cells (Menezes et al., 2018; Persaud et al., 2016). Our previous
studies have shown that recombinant bioactive IL-24 protein as well as secreted IL-24
protein (generated from Ad.IL-24-infected cells) exerts cancer-specific killing through a
mechanism identical to Ad.IL-24 infection (Sauane et al., 2008). Interleukin 24 (IL-24) is
a tumor suppressor protein that is currently in phase II clinical trials (Persaud et al., 2016).
We have shown that IL-24 releases calcium (Ca2+) from ER-stores; induces ROS and
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ceramide production; and induces inhibitory phosphorylation of eIF2-alpha (Persaud et
al., 2017; Sauane et al., 2008, 2010). We also have demonstrated that S1R interacts with
IL-24 and that IL-24:S1R complex is a critical upstream signal for IL-24-induced ER
stress, calcium mobilization, and notably, phosphorylation of eIF2- alpha and apoptosis
in cancer cells (Do et al., 2013). Consistent with our findings, Bina and colleagues have
recently shown the interaction of IL-24 and S1R in an in silico analysis (Bina et al., 2017).
Here we show that IL-24 causes inhibition of eIF4A in a wide variety of cancer cells.
To address the physiological role of eIF4A in IL-24-induced apoptosis, we used
overexpression of eIF4A. We demonstrate that IL-24 induces apoptosis through eIF4A
inhibition, and mitochondria dysfunction. Importantly, the translation of mRNAs bearing
long and structured 5’UTRs, such as the cell cycle regulators Cdc25C, c-myc, and
ornithine decarboxylase (ODC), and the survival promoting proteins Bcl-2, Mcl1, Birca5,
and X-linked inhibitor of apoptosis (XIAP), was reduced as a result of down-regulation
of eIF4A triggered by IL-24. These results demonstrate that eIF4A plays a major role in
IL24-mediated apoptosis in cancer cells. We show that eIF4A is required for IL-24induced apoptosis, whereby it acts by selective reduction of translation was observed for
mRNAs harboring strong to moderate secondary structures in their 5’-untranslated
regions (5’UTRs), including mRNAs encoding proliferation- and survival-promoting
proteins.
We also show that downregulation of eIF4A is required for IL-24-induced mitochondria
dysfunction. Our data here provide strong evidence that S1R is a critical upstream signal
for IL-24-induced eIF4A down-regulation, the translation of mRNAs bearing long and
structured 5’UTRs, mitochondrial dysfunction and apoptosis in cancer cells.
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3.2 Results
3.2.1 IL-24-Dependent Inhibition of eIF4A Is Necessary to Mediate Apoptosis
Two major events are rate-limiting in translation initiation: the formation of the ternary
complex (eIF2, GTP, Met-tRNAi) binds the 40S ribosomal subunit, and the assembly of
the eIF4F complex on the mRNA cap (Hinnebusch et al., 2014). We have previously
demonstrated

that

IL-24

causes

inhibition

of

translation,

mediated

through

phosphorylation of eIF2-alpha (Persaud et al., 2017). Furthermore, phosphorylated eIF2alpha depletes the ternary complex necessary to initiate a new round of translation
(Persaud et al., 2017). As we suggested, it is plausible that the effect of IL-24 on
translation regulation is also related to a broader effect of IL-24 on translation regulation,
possibly involving molecular players other than eIF2-alpha (Persaud et al., 2017). Now,
we demonstrate for the first time that IL-24 inhibits eIF4A protein expression level in
prostate cancer cells (DU-145), melanoma (HO-1), breast cancer cells (MCF-7), and
cervical cancer cells (HeLa) (Figure 7A). This inhibition could be via multiple mediators
such as PDCD4 and 15d-prostaglandin-J2. PDCD4 as tumor suppressor has been known
to inhibit translation for more than a decade but it still remains unknown the exact
mechanism by which it exerts this translation inhibition. One possible mechanism is that
PDCD4 directly binds to and holds eIF4A to prevent it from form the eIF4F complex
during translation initiation step as well as inhibiting eIF4A helicase activity involved in
cap-dependent translation (Yang et al., 2003; Matsuhashi et al., 2019). Thus, IL-24 could
stimulate PDCD4 production, which in turn inhibits and later decreases eIF4A level in
cancer cells. Whereas for 15d-prostaglandin-J2, it has been shown to disrupt the
interaction between eIF4A and eIF4G, preventing the eIF4F complex formation, which
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limits mRNA translation and thereby limiting protein production and proliferation in
cancer cells (Yun et al., 2018). Hence it is reasonable to hypothesize that IL-24
overexpression can increase 15d-prostaglandin-J2 level in cancer cells to inhibit eIF4A
level. IL-24 exposure also reduced viability of cancer cells (Figure 7B left panel) and
apoptosis (Figure 7B right panel and Figure 1D). In addition, caspase-3 was detected in
the same cancer cells to show IL-24 killing effect.
Next, the requirement of eIF4A down-regulation for IL-24-induced apoptosis was
analyzed by IL-24 treatment in cells overexpressing eIF4A. We investigated the
inhibitory action of IL-24 on cell growth (Figure 7C left panel) and apoptosis (Figure 7C
right panel and lower panel) on HeLa cells overexpressing eIF4A and control cells. Our
data suggests that overexpression of eIF4A can restore cells from apoptosis and viability
to control level, suggesting cell rescue from IL-24 treatment. This data is reinforcing the
importance of eIF4A for cancer cells, but how eIF4A is involved in IL-24’s cancer cell
killing effects will be further investigated and explained in later parts of this thesis. Taken
together, these results show that down regulation of eIF4A is responsible for the
inhibitory effect of IL-24 on cell growth and apoptosis.
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Figure 7. IL-24-mediatd down-regulation of eIF4A is necessary to mediate apoptosis. (A) Melanoma (HO1), breast (MCF-7), prostate (DU-145) and cervical cancer cells (HeLa) were treated for 24 h with Ad.IL24 (100 pfu per cell) or Ad.vector (100 pfu per cell). Cell extracts were subjected to Western blot analysis
to detect eIF4A, eIF4G, eIF4E and β-actin protein. (B) Cells were treated as described in (A), and cell
viability was determined by trypan blue exclusion assay 4 days after treatment (left panel). Numbers
represent the ratio of specific treatments to values in control cells (Ad.vector). Results of cell counting by
trypan blue exclusion assay are plotted as mean ± SD of three independent experiments. *, p < 0.001
comparted to Ad.vector. Cells were treated as described before, and then assayed for cell death using
Annexin V staining a measure of apoptosis, and it was determined 48 h later by FACS analysis using the
CellQuest software (Becton Dickinson). An average of three independent experiments is shown ±SD (right
panel) *, p < 0.001 comparted to Ad.vector. (C) HeLa cells overexpressing eIF4A or control cells were
treated with Ad.IL-24 (100 pfu per cell), and cell viability was determined by trypan blue exclusion assay.
Numbers represent the ratio of specific treatments to values in control cells (Ad.vector). An average of
three independent experiments is shown ± SD (left panel). *, p < 0.05 comparted to Ad.vector. Cells were
treated as described in upper panel, and then assayed for cell death using Annexin V staining, and a
measure of apoptosis was determined by FACS (right panel) *, p < 0.05 comparted to Ad.vector. Cells
were treated as described in upper panel, cell extracts were subjected to Western blot analysis to detect
cleaved caspase-3 and β-actin protein. (D) Melanoma (HO-1), breast (MCF-7), prostate (DU-145) and
cervical cancer cells (HeLa) were treated for 24 h with Ad.IL-24 (100 pfu per cell) or Ad.vector (100 pfu
per cell). Cell extracts were subjected to Western blot analysis to detect cleaved caspase-3 and β-actin
protein.
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3.2.2 IL-24 Appears to Affect Translation of mRNAs with Long, but Not Short,
5’UTRs
It has been established that eIF4A promotes the translation of mRNAs with long and
structured 5’UTR features (Dai et al., 2017; Heerma-van-Voss et al., 2017). Translation
initiation protein complexes mediate the recruitment of the 40S ribosomal subunit to the
start codon in eukaryotic mRNA. Translation is primarily regulated at the initiation stage
via the coordinated activity of translation initiation factors. Translation can be classified
into cap-dependent or conventional and cap-independent or internal ribosome entry site
(IRES) mediated based on specific structures in the mRNA itself (Lizuka et al., 1994;
Pause et al., 1994; Van Der Kelen et al., 2009; Filbin et al., 2009; Akirtava et al., 2020;
Rios-Fuller et al., 2020; Chen et al., 2020). Many translation initiation factors (eIFs)
mediate the binding of mRNA to the ribosome, detecting the AUG start codon in the 5′
untranslated region (5′UTR) of the mRNA and binding of transfer RNAs, thus playing
crucial roles in the translation machinery. Regulatory elements in the mRNA, especially
sequence elements or secondary structures in 5’and 3’untranslated regions (UTRs),
may block or recruit ribosomes and eukaryotic initiation factors (eIFs) to enable gene
expression. The eukaryotic mRNA “cap” is a 7-methylguanosine on the first (5′end)
nucleotide of the mRNA molecule and regulates cap-dependent translation. Some
mRNAs with an extremely short 5’ UTR, known as translation initiator of short 5’UTR
(TISU), may undergo cap-independent translation initiation through internal ribosome
entry sites (IRESs). Those mRNA with IRES can be translated with or without the
requirement of any canonical initiation factor (Pause et al., 1994; Filbin et al., 2009).
Some mRNAs lack a 5’ UTR, the case of all mRNAs in mitochondria (Temperley et al.,
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2010). The protein complex eIF4F mediates cap-dependent translation. The eIF4F
complex is comprised of eIF4A (an RNA-helicase that unwinds the 5’ UTR), eIF4E
(binds the mRNA 5′ cap structure), and eIF4G (scaffolding protein for eIF4A, eIF4E,
and other initiation factors). eIF4F facilitates the recruitment of ribosomes to the mRNA.
Activity of the RNA-helicase eIF4F is required for unwinding the mRNAs 5′ UTR
secondary structure, which allows eIF4F to scan the mRNA for the AUG codon, so that
translation can start (Pestova et al., 2001; Prevot et al., 2003; Lee et al., 2012;).
To confirm that IL-24 translationally down-regulates expression of long and structured
5’UTR mRNAs, HeLa cells were co-transfected with Renilla (control) and Firefly FF)
luciferase reporters harboring structured 5’UTRs or unstructured 5’UTRs. The FF
reporters used were: IRF7 [5’UTR]-FF construct, which is long and translated in an
eIF4E-dependent manner); ATP5O [5’UTR]-FF construct, containing a 4-nt portion of
the TISU element (TISU: Translation Initiator of Short 5’ UTR. A sequence context
flanking the translation start site regulating translation initiation for mRNAs with short 5’
UTR, usually ranging from 4 to 45 nucleotides) upstream of the initiation codon; ATP5O
[TISU]-FF construct with a disrupted TISU element; ATP5O [5’UTR]-SL-FF construct,
with a stable stem-loop structure (which is translated in an eIF4A-dependent manner);
UQCC2 5’UTR construct without a TISU element; and NDUFS6 5’UTR construct with
only a portion of the TISU element upstream of the initiation codon (Table 1).

Table 1. List of primers used to generate luciferase reporter constructs.
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As shown in Figure 8, the main effect of treatment with IL-24 was seen on ATP5O
[5’UTR]-SL-FF (Figure 8B) construct whose firefly luciferase activity was strongly
repressed, suggesting inhibition of translation of this construct while other constructs
showed smaller effects from IL-24 treatment. IL-24 had no effect on control Renilla
luciferase. In addition to the previous results that IL-24 inhibits eIF4A, the following
results of these assays suggest that IL-24 inhibits eIF4A expression (Figure 7A), which
leads to inhibition of translation of mRNAs with long and structured 5’UTRs (Figure 8).
As the other constructs do not possess structured or long 5’UTR, they do not require
eIF4A to linearize and unwind, hence it is aligned with the fact that their expression
levels are not significantly affected by IL-24 treatment. However, in order to further
prove that the loop and complex structure in construct 2 is the reason why its expression
is inhibited by IL-2 treatment, we would mutate the sequence in the loop to disrupt the
structure, linearizing the gene construct 2, and then test its expression level under IL-24
treatment. And if its expression level is still inhibited by IL-24 treatment, then the
structure and loop is not the reason for its inhibition, whereas if its expression level is not
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affected as much, then it would be reasonable to say that the complex structure and the
loop is the reason for the translation inhibition and eIF4A is a key mediator in this
inhibition.

A

B

C

D

E

F

Figure 8. IL-24 appears to reduce translation of mRNAs harboring structured 50UTRs. HeLa cells were
transfected with firefly (FF) reporters harboring: (A) ATP5O 50UTR with a proximal portion of TISU
element before the initiation codon (ATP5O [50UTR]-FF); (B) ATP5O 50UTR followed by a stem-loop
structure (ATP5O (50UTR)-SL-FF); (C) IRF7 50UTR (IRF7 (5;UTR)-FF); (D) ATP5O 50UTR with a full
TISU element (ATP5O (TISU)-FF); (E) NDUFS6 50UTR (NDUFS6 (50UTR)-FF); or (F) UQCC2 5
0UTR (UQCC2 (50UTR)-FF). As a control, cells were cotransfected with a Renilla reporter. Cells were
treated for 24 h with Ad.IL-24 (100 pfu per cell) or Ad.vector (100 pfu per cell). Each experiment was
performed in independent triplicates, each consisting of three replicates, and data are shown as mean ± SD.
p < 0.001 comparted to Ad.vector. RLU, relative light units.
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3.2.3 IL-24 Appears to Reduce Translation of mRNAs Harboring Structured
5’UTRs
Expression of most proteins bearing long and structured 5’UTRs, such as the cell cycle
regulators and the survival promoting proteins is translationally controlled and is highly
dependent on the activity of the helicase eIF4A that function to unwind long and
structured 5’ ends of mRNAs. To determine if IL-24 translationally down-regulates such
mRNAs, we performed Western blot and quantitative real-time PCR analyses of lysates
from HeLa cells treated with IL-24 or control (Ad.vector). Figure 9 shows that IL-24
significantly reduced the expression of proteins that are involved in cell proliferation (e.g.,
Cdc25C, c-myc, and ornithine decarboxylase), and of survival promoting proteins (e.g.,
XIAP). This inhibition could be due to the structures and length in their respective
mRNAs 5’UTR. Whereas the expression of housekeeping proteins such as Beta-actin,
GAPDH, and Beta-tubulin was not affected as they do not have long and structured
5’UTR (Figure 9A). This is also in accordance with the notion that translation initiation
inhibitors preferentially inhibit oncogenic proteins production. Although the rapid
turnover of ODC, the effect of IL-24 on ODC down-regulation is not absolute. It is
plausible that this effect involves other molecular players such as antizyme-1, and
localization of ODC in non-synchronized HeLa cells. In HeLa cells that overexpress
eIF4A, IL 24 did not affect the levels of Cdc25C, c-myc, ornithine decarboxylase, and
XIAP expression (Figure 9D), suggesting the protective effect of eIF4A on those mRNAs’
translation. Down-regulation of these proteins was likely at translation level because IL24 has minimal effects on the levels of the respective mRNAs (Figure 9B). These
findings are consistent with the notion that inhibitors of eIF4A preferentially affect the
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expression of proteins involved in cell proliferation and survival since they possess long
and structured 5’UTR in their mRNAs, which require eIF4A to straighten and unwind for
efficient translation to occur. This further proves the importance of eIF4A’ role in the
previous inhibition of gene construct, which also requires this subunit to unwind and
straighten the 5’UTR of the target mRNA. Also, this provides some insights about the
reason why IL-24 only affects cancer cells and not normal cells. It could be that IL-24
can inhibit eIF4A, which is more important for oncoproteins production and not housekeeping proteins, so cancer cells, which are more dependent on oncoproteins than normal
cells, are affected by IL-24 treatment.

Figure 9. IL-24 treatment leads to reduction of mRNAs harboring structured 50UTRs. (A) HeLa cells were
treated with Ad.IL-24 (100 pfu per cell) or Ad.vector (100 pfu per cell) for 72 h, and lysates were prepared
and probed with antibodies specific to cdc25, c-myc, ODC, XIAP, GAPDH, α-tubulin, and β-actin. (B)
HeLa cells were incubated with Ad.IL24 (100 pfu per cell) or Ad.vector (100 pfu per cell), and expression
of cdc25, c-myc, ODC, XIAP, GAPDH, α-tubulin, and β-actin mRNA was determined by real-time PCR.

3.2.4 IL-24 Treatment Leads to Mitochondrial Dysfunction
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It has been established that inhibition of eIF4A triggers mitochondrial-mediated apoptosis
by inhibiting translation of mRNAs with long 5’UTRs encoding proteins that maintain
mitochondrial structural integrity (e.g., Bcl-2, Mcl1, and BIRC5) (Gandin et al., 2016;
Matassa et al., 2013). Therefore, we investigated the effects of IL-24 on mitochondrial
function. HeLa cells were treated with IL-24 for 72 h and mitochondrial membrane
potential was measured using tetramethylrhodamine ethyl ester (TMRE), which can only
accumulate in mitochondria when they are active. We found that IL-24 treatment induced
depolarization of mitochondria (Figure 10A) as well as down-regulation of proteins
implicated in the maintenance of the integrity of the mitochondrial outer membrane
(Figure 10B left panel). These proteins share a critical characteristic of having complex
5’UTR in their respective mRNAs, which would need eIF4A to process before translation
can happen. Down-regulation of proteins implicated in the maintenance of the integrity of
the mitochondrial outer membrane was likely translational because IL-24 has minimal
effects on the levels of the respective mRNAs (Figure 10B right panel). In order to
confirm that this inhibition on protein levels is due to limited mRNA translation and not
by more degradation by lysosomes, future experiments will be included to block
lysosomes and then test these proteins levels in IL-24 treatment and control. The
requirement of eIF4A down-regulation for IL-24-induced mitochondria dysfunction was
analyzed by IL-24 treatment together with overexpression of eIF4A. The action of IL-24
on mitochondria dysfunction was tested in HeLa cells overexpressing eIF4A, which
shows that overexpression of eIF4A can rescue the mitochondrial dysfunction as well as
disrupted membrane potential (Figure 10C). These results together suggest that inhibition
of eIF4A expression is responsible for the effect of IL-24 on mitochondria membrane
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disruption and dysfunction. In addition, overexpression of eIF4A has shown an extended
restore of expression of the gene construct with loop structure in 5’UTR, reinforcing the
importance of eIF4A in the translation inhibition effects by IL-24 (Figure 10D). With the
dysfunction and membrane disruption of mitochondria, cells will initially try to repair
and safe them, but when the damage is beyond cell repair capability, autophagy will
come in to recycle the impaired mitochondria in order to keep the cells functional and
alive. Given that IL-24 is able to disrupt mitochondrial membrane and function when
killing the cancer cells, it is possible that during this process, autophagy is also inhibited
by IL-24 and damaged mitochondria will accumulate inside the cancer cells, leading to
apoptosis eventually. To test this hypothesis, we would check autophagy markers
including ATGs, Beclins and LCs by Western Blotting and immunostaining or by
visualization with electron microscopy to see if there is any change of autophagosome
structures inside cancer cells after IL-24 treatment or control treatment. To prove the
hypothesis, we would observe there are decreased markers level in treatment compared
with control cells. And in order not to miss the correct time point when this phenomenon
happens, we need to perform a time-course experiment to catch that perfect timing. But if
we don’t observe that decrease, it might be because autophagy is not involved in this
process and we need to pursue another path by comparing cytochrome c levels after Il-24
treatment or control treatment and see if that is the direct reason for cancer killing by IL24.
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Figure 10. IL-24 treatment leads to mitochondrial dysfunction. (A) HeLa cells were treated with Ad.IL-24
(100 pfu per cell) or Ad.vector (100 pfu per cell) for 72 h. Mitochondrial membrane potential (MMP) was
analyzed by monitoring TMRE fluorescence intensity. Results are presented as mean ± SD (n = 3) *, p <
0.05 comparted to Ad.vector. (B) HeLa cells were treated with Ad.IL-24 (100 pfu per cell) or Ad.vector
(100 pfu per cell) for 72 h, and lysates were prepared and probed with antibodies specific to Bcl2, Mcl1,
BIRC5, and β-actin (Left panel). HeLa cells were incubated with Ad.IL24 (100 pfu per cell) or Ad.vector
(100 pfu per cell), and expression of Bcl2, Mcl1, BIRC5, and β-actin mRNA was determined by real-time
PCR (right panel). (C) HeLa cells overexpressed eIF4A or control cells were treated with Ad.IL-24 (100
pfu per cell) or Ad.vector (100 pfu per cell) for 72 h. Mitochondrial membrane potential (MMP) was
analyzed by monitoring TMRE fluorescence intensity. Results are presented as mean ± SD (n = 3) *, p <
0.05 compared to Ad.vector. (D) HeLa cells overexpressing eIF4A cells were transfected with firefly (FF)
reporters harboring ATP5O 50UTR followed by a stem-loop structure (ATP5O (50UTR)-SL-FF). As a
control, cells were cotransfected with a Renilla reporter. Cells were treated for 24 h with Ad.IL-24 (100 pfu
per cell) or Ad.vector (100 pfu per cell). Luminescence was monitored 48 h post-transfection. Data for
Firefly luminescence normalized to Renilla luminescence. Each experiment was performed in independent
triplicates, each consisting of three replicates, and data are shown as mean ± SD. *, p < 0.005 comparted to
Ad.vector. RLU, relative light units.

3.2.5 IL-24-Dependent Sigma 1 Receptor (S1R) Mediate eIF4A Down-Regulation,
Translation of mRNAs Harboring Structured 5’UTRs and Mitochondrial
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Dysfunction
S1R is a protein chaperone, through whose regulation by specific ligands can have either
cytoprotective or cytotoxic effects (Su et al., 2016). S1R agonists bind to S1R and
promote cellular survival by preventing oxidative stress, while conversely, S1R
antagonists, bind to S1R and inhibit tumor cell survival and induce apoptosis (Persaud et
al., 2016). We have demonstrated that S1R is the common upstream initial signal
transduction molecule involved in IL-24-induced cancer-specific apoptosis (Do et al.,
2013). We have determined that IL-24 action in cancer cells is mediated by an
antagonistic effect of IL-24 on S1R. S1R antagonist-mediated cell death is inhibited by
the prototypic S1R agonist SKF10047 or by overexpression of S1R (Persaud et al., 2016;
Su et al., 2016). Therefore, we determined the possible role of S1R in the effect of IL-24
on eIF4A down-regulation as well as mitochondria dysfunction. To that purpose, HeLa
cells were transfected with S1R-expressing construct or treated with S1R agonist
(SKF10047), and the action of IL-24 on eIF4A down-regulation as well as mitochondria
dysfunction was tested. As shown in Figure 11, S1R agonist SKF10047 blocks Ad.IL-24mediated eIF4A down-regulation (Figure 11A, C), blocks mitochondrial dysfunction
(Figure 11B) as well as translation of mRNAs with long 5’UTRs (Figure 11D). The
requirement of S1R for IL-24-induced apoptosis was analyzed by IL-24 treatment along
with S1R agonist SKF10047 or by overexpression of S1R and caspase-3 again was used
to represent cell apoptosis under IL-24 treatment (Figure 11E). These results show that
IL-24-mediated eIF4A down-regulation under the control of S1R as important mediators
of apoptosis, translation of mRNAs with long 5’UTRs as well as mitochondrial
dysfunction. The follow-up experiments will be conducted to investigate the mechanisms
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by which S1R cam rescue the inhibition by IL-24 on cancer cells survival, mRNA
translation as well we mitochondrial membrane dysfunction. One of the possible
directions is to study the calcium transport between ER and mitochondria as it is an
essential way by cells to cope with stress and also regulated by S1R. We would test by
staining calcium content in ER and mitochondria and see if there is any shift of calcium
between different cell compartments.

Figure 11. IL-24-dependent Sigma 1 Receptor (Sig1R) mediate eIF4A down-regulation, translation of
mRNAs harboring structured 50UTRs and mitochondrial dysfunction. (A) HeLa cells were transfected with
firefly (FF) reporter harboring ATP5O 50UTR followed by a stem-loop structure (ATP5O [50UTR]-SLFF). Cells were cotransfected with a Renilla reporter. Cells were incubated with the Sig1R agonist
(SKF10047) or overexpression of Sig1R with or without Ad.IL-24 (100 pfu per cell). Data for firefly
luminescence normalized to Renilla luminescence. Each experiment was performed in independent
triplicates, each consisting of three replicates, and data are shown as mean ± SD. *, p < 0.05. RLU, relative
light units. (B) HeLa cells were treated as described in (A). Mitochondrial membrane potential (MMP) was
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analyzed by monitoring TMRE fluorescence intensity. Results are presented as mean ± SD (n = 3). *, p <
0.05. (C) HeLa cells were incubated with the indicated conditions. Cells were collected, protein purified,
and subjected to western blot analysis to detect eIF4A, eIF4G and eIF4E protein. (D) HeLa cells were
treated as described in (A), and lysates were prepared and probed with antibodies specific to cdc25, c-myc,
ODC, XIAP, Bcl2, Mcl1, BIRC5, and β-actin. (E) HeLa cells were treated as described in A, and lysates
were prepared and probed with antibodies specific to cleaved caspase-3 and β-actin.

3.3 Discussion
Aberrant translation initiation has a profound impact on malignancy in the form of
malignant transformation and maintenance (Hinnebusch et al., 2016; Bhat et al., 2015;
Parra et al., 2017; Lindqvist et al., 2017; Mamane et al., 2006; Sonenberg et al., 1993).
Hence translation initiation could provide an efficient mechanism to treat cancers. This
work reports a previously unrecognized mode of inhibition of translation initiation
whereby IL-24 inhibits eIF4A to induce apoptosis in cancer cells. Specifically, we
demonstrate here that IL-24 treatment preferentially inhibits the translation of mRNAs
possessing long and structured 5’UTRs at the initiation step, which could partially
explain the cancer-specific killing effects by IL-24. In agreement with this model, our
data demonstrate that IL-24 treatment inhibits eIF4A protein expression, and therefore
inhibits the translation of mRNAs harboring structured 5’UTRs but not mRNAs with
unstructured 5’UTRs. However, the exact mechanism by which IL-24 inhibits eIF4A
remains unclear in this study, it would provide more insight in the future to uncover this
pathway and the possible mediators could be PDCD4, 15d-prostaglandin-J2 and/or eIF4B.
PDCD4, as tumor suppressor, has been known to inhibit translation for more than a
decade but it still remains unknown the exact mechanism by which it exerts this
translation inhibition. One possible mechanism is that PDCD4 directly binds to and holds
eIF4A to prevent it from form the eIF4F complex during translation initiation step as well
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as inhibiting eIF4A helicase activity involved in cap-dependent translation (Yang et al.,
2003; Matsuhashi et al., 2019). Thus, IL-24 might stimulate PDCD4 production or
phosphorylation, which in turn inhibits eIF4A level, leading to decreased translation for
oncogenes in cancer cells. Whereas for 15d-prostaglandin-J2, it has been shown to
disrupt the interaction between eIF4A and eIF4G, preventing the eIF4F complex
formation and limiting mRNA translation, and thereby limiting protein production and
cell proliferation in cancers (Yun et al., 2018). Hence it is reasonable to hypothesize that
IL-24 overexpression can increase 15d-prostaglandin-J2 level in cancer cells to inhibit
eIF4A level. While another key translation initiation factor eIF4B has been found to
enhance the affinity of eIF4A for mRNAs as well as stimulate eIF4A’s unwinding ability
and efficiency up to 10-folds (Abramson et al., 1988; Ozes et al., 2011; Merrick et al.,
2015; Pelletier et al., 2019), I would hypothesize that IL-24 overexpression treatment can
hamper eIF4B phosphorylation activity or its interaction with eIF4A in order to limit
eIF4A’s mRNA unwinding ability, which then causes decreased oncoproteins production
in cancer cells, leading to apoptosis. All these hypotheses are yet to be tested to deepen
our understanding for IL-24 in cancer management.
Moreover, we show that through the previously mentioned mechanism, IL-24 targets the
expression of specific mRNAs harboring strong secondary structures in their 5’UTRs.
These mRNAs encode proteins which function in survival (XIAP and Bcl-2) and in cell
proliferation (Cdc25C, ODC, and c-myc). Importantly, we also show that overexpression
of eIF4A confers cancer cells with resistance to IL-24-induced cell death and targets the
expression of highly structured 5’UTRs mRNAs. Thus, we provide the first direct
evidence for translational control for specific genes’ expression by IL-24 through the
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regulation of eIF4A. This is consistent with the paradigm, in the field of translational
regulation of gene expression, that down-regulation of eIF4A seems to be a promising
cancer therapeutic approach with a pronounced effect on the translation of mRNAs
encoding proteins important for proliferation, metabolism and survival, providing cancer
cells a selective advantage (Heerma et al., 2017; Cencic et al., 2016; Chu et al., 2015;
Parsyan et al., 2011; Steinberger et al., 2017). This notion has been further supported by
the research done by Dr. Chio and her team at Columbia University. In their recent study,
a synthetic rocaglate CR-1-31-B has been shown to inhibit viability, survival,
proliferation of pancreatic ductal adenocarcinoma cell lines, organoid growth and in-vivo
tumor growth, resulting in longer tumor-bearing mice survival. According their data, this
cancer cell inhibitory effect is likely through inhibition of eIF4A and does not cause
significant toxicity at systemic level in mice. One of the mechanisms by which CR-31
inhibits cancer cells and tumor growth is through eIF4A inhibition, which shifts and
redirects translation in cancer cells to the one common in normal cells. Furthermore, Dr.
Chio’s team has also established the importance of eIF4A in pancreatic ductal
adenocarcinoma maintenance as well as the critical role of eIF4A-dependent translation
in pancreatic ductal adenocarcinoma (Chan et al., 2019).
In another study conducted in 2018, one of the classic eIF4A inhibitors silvestrol’s
analogs EC143.29 and EC143.69 showed efficient blockade in protein synthesis
regardless of 4E-BP1 expression status. Given that 4E-BP1 is a pivotal translation
repressor that is commonly lost in pancreatic ductal adenocarcinoma to support and
maintain malignancy, this 4E-BP1-independent inhibition on pancreatic ductal
adenocarcinoma by silvestrol’s derivatives provides such a promising and favorable

- 51 -

potential therapeutic mechanism. Moreover, inhibition of 4E-BP1 by EC143.29 and
EC143.69 also inhibits CDC6, which is a key regulator for DNA replication and repair,
leading to limited cell proliferation and replication, possibly contributing to cancer cell
and tumor growth inhibition by silvestrol both in vitro and in vivo. It is noteworthy that
this set of in vivo experiments were conducted in C57BL/6J mice, which is the mice
strain we use for our in vivo study with PD-L1, so this study also provides us specifically
more confidence and guidance for our in vivo study (Müller et al., 2018).
eIF4A1 is more abundant and better studied than eIF4A2. The two isoforms exhibit
similar biochemical activities. However, their roles may not be equivalent. Notable
differences include the following: eIF4A1 is predominantly synthesized during active cell
growth, whereas eIF4A2 is produced during growth arrest; Suppression of eIF4A1 leads
to increased eIF4A2 levels, but this change is insufficient to compensate for the ensuing
cell death associated with eIF4A1 loss; eIF4A1 is essential for cell survival, but eIF4A2
is not (Williams-Hill et al., 1997; Lu et al., 2014; Raza et al., 2015; Nebigil et al., 2020;
Shen et al., 2020). While eIF4A1 seems to be more important for cell function than
eIF4A2 and inhibition of eIF4A1 by IL-24 has such a potent impact on cancer cell
proliferation and survival, it is worth investigating what happens to eIF4A2 when IL-24
is downregulating eIF4A1 in cancer cells. Based on the present advancement in the field,
I would hypothesize that upon IL-24 treatment, eIF4A2 is transcribed and translated into
protein more than usual so that cancer cells can try to compensate for translation
efficiency as both isoforms have been shown to participate in ribosome recruitment and
translation (Robert et al., 2020), followed by cells transitioning from growing status to
static status for a period of time before they eventually turn on apoptotic pathways and
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die. In order to test this hypothesis, we would perform RT-PCR 12, 24 and 36 hours after
IL-24 treatment to measure the mRNA levels of eIF4A2 as well as Western Blotting to
determine protein levels of eIF4A2. Also, we would determine which cell cycle phases
the cells are in at those time points too to match the eIF4A2 expression levels with cell
growth status.
Despite the progresses with the two major pathways IL-24 modulates, the way in which
the two major regulatory branches, which regulate translation, ternary complex and eIF4F
assembly, are coordinated remains largely unknown. Interestingly, Gandin et al.
demonstrated a coordinated regulation of eIF2-alpha and eIF4E via CK2 and mTORC1
(Gandin, et al., 2016). Our group recently demonstrated the role of IL-24 in inhibition of
translation, mediated through phosphorylation of eIF2-alpha (Persaud et al., 2017).
Consistent with this and with the new results reported here, both the ternary complex
formation and eIF4F complex branches are inhibited by IL-24. It is yet not clear if both
facets of translation initiation can be modulated, together or separately by one or more
upstream signals triggered by IL-24.
On the other hand, to characterize the signal transduction pathways responsible for the
downregulation of eIF4A by IL-24, we focused on the upstream pathways involved in IL24 induced apoptosis. Our data here provide strong evidence that the IL-24 downregulation of eIF4A expression is Sigma 1 Receptor (S1R)-dependent (Figure 5). Also, in
this study, we demonstrate that IL-24 induces eIF4A-dependent and S1R-dependent
mitochondrial depolarization (Figure 11). Therefore, it is plausible that S1R coordinates
TC and eIF4F complex assembly triggered by IL-24. Future research is required to
delineate the mechanisms by which S1R down-regulates eIF4A expression triggered by
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IL-24 and to investigate the mechanisms by which S1R mediated through both
phosphorylation of eIF2-alpha and de-phosphorylation of 4E-BP1.
In summary, IL-24 treatment has distinct advantage over the other general and
conventional chemotherapies that usually target a wide range of cells in patients, which
tend to cause significant side effects including bone marrow suppression and immune
suppression, leading to infection. On the other hand, IL-24-mediated inhibition of
translation initiation is not limited to any specific oncogene as many other approaches,
but effective to an array of oncogenic proteins, which provides the potential to overcome
the obstacle of resistance to treatment (Weinstein et al., 2002). IL-24-mediated inhibition
of translation initiation could be harvested for either solo therapy or combination therapy
with other therapies that also target translation initiation factors to amplify the inhibition
on cancer cells.
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Chapter 4: IL-24 suppresses tumor growth by inhibiting checkpoint PD-L1
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4.1 Introduction:
Immune system surveys tumors and eliminate many early tumors, but tumors evolve to
evade immune system. Proteins produced by cancer cells that can suppress the immune
system to inhibit anticancer immune responses and these proteins are called checkpoints.
CTLA-4 (cytotoxic T lymphocyte-associated molecule 4) and PD-1 (programmed cell
death protein 1) expressed on T lymphocyte function as immune system checkpoints that
negatively regulate T lymphocyte activation. These inhibitory T lymphocyte receptors
bind to effector molecules on tumor cells or antigen-presenting cells, thereby suppressing
tumor-reactive T lymphocyte function. Therapies targeted against these negative
immunologic regulators (checkpoints) are called immune checkpoint blockade therapies,
which have been showing enlightening progress and are likely to be a major part of
management for various cancer patients. The most promising ones include anti-PD-1
(programmed cell death protein 1) and anti-CTLA-4 (cytotoxic T lymphocyte-associated
molecule 4).
PD-1 is a checkpoint of T lymphocyte when engaged with its ligands PD-L1. Upon
binding between ligand PD-L1 and receptor PD-1, kinase-signaling pathways that
normally cause activation of T-cells are inhibited, hence, leads to inhibition of
proliferation and infiltration of T cells (Ishida et al., 1992; Freeman et al., 2000; Keir et
al., 2006). The notion here is that if the interaction between PD-1 and PD-L1/2 or the
expression level of PD-L1 is blocked, then T cells will not be inhibited and instead can
remain activated and go fight cancer cells as usual.
Increasing body of research exploiting ICBs has been underway for the past decade
especially during the past few years after this method was awarded with Nobel prize.
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Chen and his team studied the relationship between PA-L1 and PD-1 expression levels
and oral squamous cell carcinoma and found that high expression of the pair is highly
associated with suppressed immune response by T cells, faster tumor growth, resistance
to treatment and poor prognosis (Chen et al., 2020). In addition to its solo treatment, antiPD-L1/PD-1 therapy has also been studied extensively in combination treatment for
cancer patients as well. It was found that the efficacy and efficiency of anti-PD-L1
treatment regimen is augmented when Mitomycin C is added to the regimen for small cell
lung carcinoma (Luo et al., 2020).
In the effort trying to determine the value of anti-PD-L1 treatment in vivo, scientists have
widely used a strain of mice C57BL/6J. Turnis and colleagues have shown that inhibition
of IL-35 can limit transplantable tumors’ growth of various types in C57BL/6J mice.
Jonathan and his colleagues have proved that a combination between IL-12 and anti-PDL1 antibody has a better response in C57BJ/6L mice injected with MC38 cells than either
treatment alone (Spencer et al., 2017; Jonathan et al., 2017; Turnis et al., 2016). We want
to define if IL-24 can inhibit production of PD-L1 and if this inhibition can lead to T cells
infiltration, activation, proliferation as well as suppressed tumor growth in vivo. Here we
use C57BL/6J mice and MC38 mice colon cancer cells, which have been used by other
groups for the purpose of testing immune checkpoint blockade therapies. Our preliminary
data suggest that IL-24 can inhibit total PD-L1 expression level in vitro and colon tumor
growth in vivo. Notably, this is a preliminary experiment with only two mice to test,
optimize and find the best settings for our system, so there is no statistic study to be
included here. But due to the promising and favorable results we discovered here, the
next step would be to expand mice group to collect statistically significant results as well
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to further study the effects by IL-24 on tumors in vivo.

4.2 Results
4.2.1 IL-24 inhibits PD-L1 expression in vitro
Our previous study suggested that IL-24 inhibits eIF4A expression levels in vitro (Zhong
et al., 2018). In addition, Cerezo and colleagues demonstrated that inhibition of eIF4A
contributes to PD-L1 downregulation in melanoma (Cerezo et al., 2018). Here we show
for the first time that IL-2 inhibits total PD-L1 expression in vitro (Fig.12). Due to the
fact that PD-L1 is known to only bind to PD-1 receptor when it is present on the cell
surface and inactivate T cells (Iwai et al., 2002; Topalian et al., 2013), the next
reasonable step in understanding the role of IL-24 in immune check point blockade
would be to define if IL-24 specifically reduces the expression level of PD-L1 on the
cancer cell surface to prevent T cell inactivation by the binding between PD-L1 and PD-1
with immunostaining.
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Figure 12. IL-24 inhibits PD-L1 expression in vitro. DU145 cells were infected with Ad.IL-24 virus on
Day1 (150pfu). Cells were treated with IFN-gamma (IFN-g) on Day2. Cells were collected, protein purified,
and subjected to western blot analysis to detect PD-L1 and beta-actin (b actin). The experiment was
replicated three times.

4.2.2 Animal study experiment design
Following the in vitro study, we proceeded to an animal study in order to further
determine if IL-24 can inhibit PD-L1 and tumor growth in vivo. For this purpose,
following the protocol established by Wei SC. and his colleagues (Wei et al., 2017), we
did a preliminary experiment with two female C57BL/6J mice to test and optimize the
settings in our system, including the number of cancer cells for injection, virus treatment
dosage and length of the experiment. We injected mouse colorectal cancer MC38 cells
into the right flank of the mice to form tumors, followed by treatment with either empty
adenovirus or IL-24 adenovirus. We measured the tumor size every other day and then
analyzed the tumors for size and weight after dissection from mice (Fig. 13).

Figure 13. Mice experiment design. Two 8-week old C57BL/6J female mice were put in one cage and
allowed to accommodate for 2 weeks prior to cancer cells injection. On day 0, 1x10 10 MC38 cells were
mixed with 100 µL PBS and injected subcutaneously into the right flank of each mouse. Mice tumors were
observed and measured every other day. On day 18, tumors were palpable and sizable in both mice, then
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185 µL of PBS with empty adenovirus was injected intratumorally in the control mouse and 185 µL of
Ad.IL-24 solution was injected intratumorally in the treatment mouse. On day 22, the mice were sacrificed
and tumors were harvested and measured for size and weight.

4.2.3 IL-24 suppresses tumor growth in C57BL/6J mice

After dissection of the tumors from the mice, we measured the weight and size of the two
MC38 tumors. Our preliminary data shows that the treatment tumor is almost half of the
control tumor in both weight and size (control tumor size 1.8 x1.25 x1.0mm, weight 1.1g,
treatment tumor size 1.4 x1.35 x0.6mm, weight 0.5g), suggesting that IL-24 is able to
suppress MC38 tumor growth in mice (Fig. 14). A possible mechanism by which IL-24
suppresses tumor growth and size is by reinvigorating T cells to recognize cancer cells
and respond to inhibit and kill cancer cells within the tumor. So next step we would
detect whether T cells are being reactivated and responding to cancer cells with IL-24
treatment. We would perform immunostaining with the tumor tissue and check levels for
T cell markers to differentiate regulatory and cytotoxic T cells. To further test the
mechanism of IL-24 on tumor growth inhibition, we would check for angiogenesis
markers EGFR within the tumor as tumor needs extremely high level of energy and
nutrient intake, IL-24 might being suppressing tumor growth by inhibiting angiogenesis
to limit resources for tumor.
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Figure 14. MC38 tumor growth is suppressed by Ad.IL-24. Mice tumors were observed and measured
every other day. (a) MC38 tumor size is suppressed in the treatment tumor compared with the control
tumor. (b) MC38 tumors were dissected and weighed on Day 22. Treatment tumor weight was suppressed
compared with control tumor. Experiment will be expanded to more mice to get statistical significance.

4.3 Discussion:
Cancer cells are supposed to be targeted by immune system such as CD4 and CD8 T cells,
but certain cancer cells develop mechanisms to evade immune system by suppressing T
cells activation, proliferation or infiltration into the tumor (Wei et al., 2017). CTLA-4 and
PD-L1 are two of the proteins used by cancer cells to inhibit immune system response
and these proteins are termed as checkpoints, thus it is reasonable to target these
checkpoints to prevent inhibitions of immune responses by malignant cells and this
approach is named immune checkpoint blockade therapy. While immune checkpoint
therapy has been shown to have significant and durable responses in clinic settings in
patients with wide range of cancer types from lung cancer, kidney cancer and advanced
melanoma, the side effects and adverse immune events are not negligible, since some
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patients have developed serious response to the treatment such as dermatologic,
gastrointestinal, hepatic and endocrinal damages (Postow et al., 2015). To alleviate these
adverse events while not compromising the treatment efficacy, more research needs to be
done to optimize the treatment in terms of dosage, scheduling and possible use of
combination of drugs.
For our group, the next step is to include more animals to collect statistically significant
data. Furthermore, we plan to incorporate mass cytometry to analyze which T cells are
activated and recruited into the tumor microenvironment as well as which cell markers on
the cell plasma membrane are either up-regulated or down-regulated by IL-24 treatment
in order to gain a better insight about how IL-24 is exerting its tumor suppression in vivo.
With mice tumors, we will also check cell markers expression levels using
immunohistochemistry to compare between control group and IL-24 treatment group.
Our first targets include TBET, TIM3, ICOS and KLRG1. TBET is a marker for CD4
effector cells proliferation, which are important effector cells fighting cancer cells in
normal situation. TIM3 is a marker for CD8 activation. ICOS is a marker for CD4 T cell
activation. KLRG1 is a marker for regulatory T cells, which are usually inhibited for the
purpose to produce more effector cells from silent T cells (Wei et al., 2017). We
hypothesize that IL-24 treatment will increase TBET, TIM3, ICOS while inhibiting
KLRG1 expression to stimulate immune system to combat cancer cells as foreign bodies.
In summation, immune check point blockade therapy, as a relatively new approach for
cancer treatment, has been gaining increasing attention across the field due to its high
efficacy, efficiency and specificity. While its detailed mechanisms are still yet to be
defined by more research moving forward, we believe that our work will contribute to
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deepen our understanding about and broaden the application of this concept either by
itself or in combination with other existing treatment regimen.
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Chapter 5: Summary and Discussion
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5.1 IL-24 is an Inhibitor of Translation Initiation in Cancer Cells
The significant roles of translation initiation factors in the development of various types
of cancers have been established by other groups (Barna et al., 2008; Chu et al., 2016;
Hinnebusch et al., 2016). Altered expression levels of translation initiation factors have
been shown to contribute to initial cell malignant transformation and later cancer cell
proliferation, invasion and metastasis (Weinstein et al., 2002; Barna et al., 2008; Miluzio
et al., 2011; Hsieh et al., 2012). Manipulation on translation initiation could thus afford a
strong mechanism employed for cancer therapeutic development.
This dissertation presents strong results suggesting that inhibition of translation initiation
with IL-24 could lead to cell apoptosis in cancer. Specifically, IL-24 inhibits eIF4A1
expression level, which reduces the efficiency of translation of a group of oncogenes’
mRNAs due to their complex 5’ UTR structures. Notably, our group show in this work
that decreased eIF4F complex by IL-24 can cause upregulation of pro-apoptotic proteins
markers such as Caspase 3. Hence, we have the first direct evidence showing
translational control of oncogenes by IL-24. This notion is in accordance with the new
census that translational regulation of specific genes expression instead of only general
rate of translation are causing cancer cells death as previously proposed (Bhat et al.,
2015).
We also present that through this mechanism, IL-24 targets the expression of specific
oncogenic proteins such as Bcl2, c-Myc, which are crucial for cancer cells to keep their
malignant behavior. This approach clearly has a significant advantage over the traditional
genotoxic chemotherapy that is toxic for all cells within the reach. On the other hand,
with the selectivity of IL-24-mediated inhibition of translation for genes, it is not limited
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to only one single oncogene as many current approaches are, but rather has an effect on
many oncogenes, which has the potential to overcome the issue of resistance to treatment
(Weinstein et al., 2002). While IL-24 has been studied extensively as a potential cancer
therapeutic, but its inhibition on translation might also have a part in its other functions
including antibacterial and antiviral effects, which still requires further investigation.
In a nutshell, the discovery of translation initiation inhibition as one of the pivotal
mechanisms of IL-24’s cancer-specific killing effect largely broadens our understanding
about this molecule and its therapeutic potential in cancer treatment.

5.2 IL-24 disrupts Mitochondrial Membrane Integrity Through Inhibition of eIF4A
As previously proved by other groups, inhibition of eIF4A contributes to mitochondrial
dysfunction and cell apoptosis (Gandin et al., 2016; Matassa et al., 2013). Here we
hypothesized and proved that IL-24 is inhibiting eIF4A, which leads to mitochondrial
dysfunction and cell apoptosis.
In this project, we show that IL-24 is able to disrupt mitochondrial membrane potential
and integrity by inhibiting translation of proteins important for maintaining the integrity
of mitochondrial membrane such as cdc25C and XIAP, not only are these proteins
important for maintaining mitochondria membrane, but they also have complex 5’ UTR
structures in their respective mRNAs that rely on RNA helicase like eIF4A to unwind
their structures to be translated. Conversely, overexpression of eIF4A is able to rescue
this mitochondrial disruption by IL-24, further suggesting that eIF4A is the mediator in
this IL-24 induced mitochondrial dysfunction.
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5.3 Sigma 1 Receptor Can Rescue Cancer Cells From IL-24’s Killing Effect
S1R, as a complex protein chaperone, can have either cytoprotective or cytotoxic effects
depending the specific ligand and environment (Su et al., 2016). Here, we present data
suggesting that S1R is a mediator in IL-24-induced cell apoptosis. Specifically, both S1R
and its agonist can rescue mitochondrial dysfunction from IL-24 and save cells from
being killed by IL-24, whose mechanism is still yet to be discovered from further study.
Meanwhile, S1R is also able to directly prevent cell death caused by IL-24 inhibition on
eIF4A. Taken together. our data is showing that S1R’s potential as a therapeutic target for
anti-cancer drug development in future cancer treatment and management.

5.4 IL-24 inhibits PD-L1 to inhibit cancer cells
PD-L1, as one of the most studied immune checkpoints, has been shown in our system to
be inhibited by IL-24 both in vitro and in vivo, leading to tumor growth inhibition and
cancer cells apoptosis. This inhibition on tumor by IL-24 through PD-L1 may provide
physicians one more option when treating cancer patients who are resistant to and/or
prone to the toxicity of traditional chemotherapies. Compared to chemotherapies and
other immunotherapies, immune checkpoint blockade method has been shown in the
clinic to have better response in a group of cancer patients with non-small cell lung
carcinoma, kidney cancer and advanced melanoma.
Currently, the biggest hurdles with developing and applying ICBs treatment are that the
treatment efficacy duration is short, recurrence rate is high, the price is not affordable and
most importantly, the application is very much limited to a small subset of cancer patients.
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In order to overcome these obstacles in order to better treat cancer patients, more research
is warranted to uncover the mechanisms of how ICBs work and why we have the current
limitations and side effects when using ICBs.

5.5 Discussion
Worldwide, cancer has been on the rise and is causing almost 10 million deaths every
year. Effective and safe therapeutic targets and treatments are in high demand to alleviate
cancer-related mortality and morbidity.
IL-24 as a multidimensional pleiotropic cytokine has the potential to be exploited either
as a therapeutic treatment in various diseases such cancer and some autoimmune diseases.
IL-24 is such an fascinating member in IL-10 cytokine family, which has well-known
anti-cancer effects in preclinical studies as well as Phase I/II clinical trials with patients
with various kinds of advanced cancers. Within a few years of its anti-cancer effect
discovery, IL-24 has had a fast progress into the clinic application where it has been
found to be safe and effective when injected intratumorally using a non-replicative type 5
adenovirus (Ad.mda-7; INGN 241) in a wide-spectrum of cancers that did not respond to
other therapies, including melanomas and advanced carcinomas (Tong et al., 2005).
Studies performed in the last two decades in many laboratories around the world are
expanding our understanding of the molecular mechanisms of IL-24 functions. New IL24 targets are being identified in the area of apoptosis and toxic autophagy, which will
facilitate development of preclinical therapeutic options that, combined with targeted
therapies, may result in enhanced anti-cancer outcomes in patients. For future research, in
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order to enhance our understanding and utility of IL-24 as a tumor suppressor with
enormous potential in clinical applications, we would need to uncover how IL-24
differentiates cancer cells from normal cells when exerting its pro-apoptotic and toxic
autophagy functions, as this would give us new and deeper perspectives about therapeutic
development. Also, genetically modifying IL-24 to boost its biological properties and
therapeutic efficacy could afford a feasible tactic for pushing this cytokine into more
clinical settings.
While translation inhibitors have already entered clinical trials for many types of cancer,
more insights into and understanding of how these inhibitors selectively suppress the
expression of key molecules like C-MYC and PD-L1, could largely accelerate the rate of
new drug discovery and clinical treatment response.
In this dissertation, I present pathways involving IL-24 such as translation initiation and
mitochondrial disruption, solidifying IL-24’s importance in cancer killing effects.
Moving forward, understanding how IL-24 exploits these pathways when killing cancer
cells in animal models and more human patients would provide the field more confidence
and support when applying it clinically (Table 2).
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Table 2: IL-24 as potential anti-cancer therapeutic in various cancers. IL-24 as a potential anti-cancer
gene has been tested in various types of cancer in human patients including breast cancer, prostate cancer,
pancreatic cancer and ovarian cancer, making it a very promising candidate as a cancer therapeutic. And in
this work, we tested this anti-cancer effect in various cancer cell lines as well we trying to define the
mechanisms by which IL-24 is able to kill cancer cells and leave normal cells intact.

So far, most of the preclinical research efforts have been put into increasing the
efficiency of delivery of IL-24 into cancer cells and boosting IL-24’s cancer-killing effect
in combination with other small molecules and other cancer treatments. In addition,
vaccinia viruses, which is widely used as vectors for infectious disease vaccines, have
been tested to treat cancer both in vitro and in vivo (Deng et al., 2018; Zhang et al., 2015).
In the future, development of more effective systemic delivery approaches for IL-24 gene
could largely expand applications of this therapeutic cytokine since most of studies
performed so far have used intra-tumoral injection of non-replicative adenoviruses
expressing IL-24 genes. In the case of metastatic disease, which is the ultimate stage of
cancer and most common cause of cancer patient death, an optimal delivery form of
therapies is highly required. Systemic application of cytokine proteins may cause severe
side effects like autoimmune response and nonspecific inflammation, which is one of the
bottlenecks during therapeutic development using these molecules. Improved drug

- 70 -

delivery methods such as UTMD and nanoparticles, to apply IL-24-centered treatments,
could provide clinicians a safer and more effective administration of this protein. Hence,
it is highly significant and of huge clinical relevance to develop methods for IL-24centered systemic treatments and test them in preclinical animal models and then patients.
More studies in different cancer types will further uncover more molecules contributing
to IL-24’s mechanisms of killing effects, thus providing new perspectives about IL-24’s
anti-cancer properties and helping further and expand use of IL-24 as a precise and safe
therapeutic in cancer patients.
As increasing amount of knowledge accumulates about pathways important for cancer
development and maintenance over the past decades, these divergent pathways reflect the
underlying cellular and molecular heterogeneity of the tumors, which eventually
converge to the dependence on the activity of eIF4F complex, which contributes to the
alterations to the oncogenes expression, driving malignant transformation, progression
and even development of resistance to many therapeutics (Figure 15).
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Figure 15: Oncogenic signaling pathways converge at cap-dependent translation initiation step at eIF4F
complex. eIF4F complex has been shown to be at the convergent position of various pathways involved in
cancer development, progression and drug resistance. eIF4A subunit inhibitors including Hippuristanol,
Pateamine A and eFT226 have been shown to inhibit translation of oncogenes involved in cell proliferation,
survival and metastasis.

Thus, exploiting this complex—the critical point of convergence for various oncogenic
stimuli—may present an effective means to overcome the heterogeneity that plagues
current cancer management. Researchers have accumulated plenty of data about the
mRNA cap structures and essential studies have defined their biologic function. It is these
essential research studies that have led us to today’s deep knowledge about targeting the
eIF4F complex, particularly for the treatment of cancer. Though, there is still a lot of
work to do to translate from basic research to clinical application, there are plenty of
opportunities to take advantage of and move forward our understanding about eIF4F
complex to develop new therapies that inhibit the translation initiation of mRNAs
encoding oncogenic proteins to better fight cancers. In summation, future studies to find
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out more details about the mechanisms and connections between IL-24 and eIF4F are
very likely to give us more options when it comes to treating various and resistant
cancers.

Figure 16. Potential pathways for T cell regulation. Various ligands, including CD40, CD70, MHCs and
their respective receptors CD40L, CD27, LAG-3, TCR, KIR, are involved in T cell activation and
inhibition regulation, providing more potential targets for ICBs therapeutics. The goal is to find out the
relationship between these ligands and their receptors expresión levels and tumor growth in order to
discover more mechanisms to inhibit tumor growth and metástasis.

Meanwhile, immune system is tightly regulated in human to maintain a fine balance
between overreaction to self, called autoimmune diseases, and under-reaction to foreign
bodies such as tumor. In the view of their highly encouraging responses in cancer patients
(Figure 17), ICBs have their own holdbacks such as autoimmune responses to digestive
system, endocrine system due to dis-inhibition on PD-L1 and CTLA-4 pathways, which
play key roles in preventing autoimmune diseases such as Grave’s disease, diabetes
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mellitus, Celiac disease and so on.

Figure 17. The application of anti-PD-1/L1 in various types of cancer. Anti-PD-L1 therapeutics have been
tested in various types of cancer including melanoma, small cell lung carcinoma, Hodgkin lymphoma and
ovarian cancer patients with promising results showing cancer remission to different extents. Some patients
stay in remission for months while others stay in remission for years.

Though some physicians have used steroids to combat this fallback, but the effects of
inhibiting immune cells activation could be counterbalancing the effects of using ICBs
treatment to fight cancer. Furthermore, many questions, including which patients are
more likely to have these adverse events, when to give patients treatment for these
adverse events, can these patients be treated with ICBs ever again, have not yet been
answered, so more communication between clinicians and researchers is needed to help
the entire human species to better understand the mechanisms of these adverse effects
and give the patients the best treatment to either prevent or alleviate them to get the best
outcome for cancer patients (Ueda et al., 2003; Prokunina et al., 2002).
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Due to its negative impacts on surviving cancer patients, clinicians need to be more
cautious with ICBs treatments at the very beginning, including choosing the proper
patients who are more likely to have more benefit from these ICBs than adverse events.
To this point, there have been a few predictive markers for effective ICB treatment
including PD-L1 expression level on tumor cell surface, microsatellite instability,
mutation in cancer cells like EGFR, CD73, CD8+ T cell infiltration into tumor
microenvironment, but due to their low reliability, low negative predictive values, vague
cutting line, clinicians are still struggling with the application of this uprising novel
treatment (Snyder et al., 2014; Larkin et al., 2015; Mahoney et al., 2015; Tokito et al.,
2016; Ishii et al., 2020). Thus, more clinical and basic research is warranted to further our
knowledge to find more predictive biomarkers for more effective and less cumbersome
immune checkpoint blockade therapy for patients suffering from cancers. This approach
will also provide more cost-effective management with better patient response to
treatment as well as less unwanted side effects that can be life threatening.
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